register_number stringlengths 11 11 | secondary_id listlengths 1 10 | url stringlengths 44 44 | brief_title stringlengths 20 290 | brief_summary stringlengths 63 5.05k | official_title stringlengths 25 483 ⌀ | intervention listlengths 1 19 | arm_intervention listlengths 1 21 ⌀ | f_condition listlengths 1 135 | sponsor listlengths 1 1 | collaborator listlengths 1 25 | experimental_drug listlengths 1 13 | study_identifier listlengths 1 7 ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT00078858 | [
{
"id_field": "org_study_id",
"id_value": [
"1668.00"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2012-00668"
]
},
{
"id_domain": "Fred Hutchinson Cancer Resear... | https://clinicaltrials.gov/study/NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | This phase I/II trial studies whether stopping cyclosporine before mycophenolate mofetil is better at reducing the risk of life-threatening graft-versus-host disease (GVHD) than the previous approach where mycophenolate mofetil was stopped before cyclosporine. The other reason this study is being done because at the pr... | Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial | [
{
"description": "Given IV",
"name": "fludarabine phosphate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"2-F-ara-AMP",
"Beneflur",
"Fludara"
],
"type": "Drug"
},
{
"description": "Undergo TBI",
"name": "total-body irradiation",
"... | [
{
"design_group_description": "CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2, and undergo TBI on day 0.<br/>TRANSPLANTATION: Patients undergo allogeneic PBMC transplant on day 0.<br/>IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 80 with taper to... | [
"Accelerated Phase Chronic Myelogenous Leukemia",
"Adult Acute Lymphoblastic Leukemia in Remission",
"Adult Acute Myeloid Leukemia in Remission",
"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
"Adult Acute Myeloid Leukemia With Del(5q)",
"Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)"... | [
"Fred Hutchinson Cancer Research Center"
] | [
"National Heart, Lung & Blood Institute",
"National Cancer Institute"
] | [
[
{
"name": "环孢素",
"lang": "CN"
},
{
"name": "Cyclosporine",
"lang": "EN"
},
{
"name": "シクロスポリン",
"lang": "JP"
}
],
[
{
"name": "磷酸氟达拉滨",
"lang": "CN"
},
{
"name": "Fludarabine Phosphate",
"lang": "EN"
},
{
... | null |
NCT06768268 | [
{
"id_field": "org_study_id",
"id_value": [
"202409024MIND"
]
},
{
"id_domain": "National Taiwan University Hospital Hsinchu Branch",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number",
"id_value": [
"114-BIH052"
]
},
{
"id_field": "acronym",
... | https://clinicaltrials.gov/study/NCT06768268 | A Dose-Image Optimization Trial Evaluating Mannitol and Voluven as Adjuncts for Indocyanine Green | The goal of this clinical trial is to exploring the use of Mannitol 20% as a solvent to prepare ICG solution, combining with Voluven, forming a hybrid small-large molecular weight solvent for protecting ICG in monomer form and stimulating lymphatic uptake simultaneously in early breast cancer patients who is indicated ... | Advanced Research on ICG Fluorescence Imaging-Guided Surgery Technique Using Mannitol and Voluven as Adjuncts | [
{
"description": "The procedure includes: (1) preparation of specific formula of ICG:Voluven solution (2) injection of ICG solution at subarelar area or peri-tumoral area (3) observation of fluorescent lymphatic drainage and retrieval of sentinel lymph nodes",
"name": "Voluven-assisted Indocyanine green flu... | [
{
"design_group_description": "The solution is prepared using Voluven as solvent, forming a 0.25 mg/mL ICG:Voluven solution.",
"design_group_title": "Pure Voluven",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
... | [
"Breast Cancer Early Stage Breast Cancer (Stage 1-3)"
] | [
"National Taiwan University Hospital"
] | [
"National Taiwan University Hospital"
] | [
[
{
"name": "甘露醇",
"lang": "CN"
},
{
"name": "Mannitol",
"lang": "EN"
},
{
"name": "D-マンニトール",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ICGMV"
}
] |
NCT02756130 | [
{
"id_field": "org_study_id",
"id_value": [
"16-000746"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2016-00596"
]
},
{
"id_domain": "Jonsson Comprehensive Cance... | https://clinicaltrials.gov/study/NCT02756130 | Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC) | This phase I/II trial studies how well birinapant and carboplatin work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back. Drugs used in chemotherapy, such as birinapant and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells,... | A Phase I/II, Single Center, Proof-of-Concept Study of Birinapant in Combination With Platinum Based Chemotherapy Targeting Recurrent High Grade Serous Ovarian Carcinomas (HGSOC) | [
{
"description": "Given IV",
"name": "Birinapant",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"TL32711"
],
"type": "Drug"
},
{
"description": "Given IV",
"name": "Carboplatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other... | [
{
"design_group_description": "Patients receive birinapant IV over 30 minutes on days 1 and 8, and carboplatin IV over 30 minutes to 1 hour on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.",
"design_group_title": "Treatment (birina... | [
"High Grade Fallopian Tube Serous Adenocarcinoma",
"High Grade Ovarian Serous Adenocarcinoma",
"Primary Peritoneal High Grade Serous Adenocarcinoma",
"Recurrent Fallopian Tube Carcinoma",
"Recurrent Ovarian Carcinoma",
"Recurrent Primary Peritoneal Carcinoma"
] | [
"Jonsson Comprehensive Cancer Center"
] | [
"TetraLogic Pharmaceuticals Corp.",
"California Institute for Regenerative Medicine"
] | [
[
{
"name": "卡铂",
"lang": "CN"
},
{
"name": "Carboplatin",
"lang": "EN"
},
{
"name": "カルボプラチン",
"lang": "JP"
}
],
[
{
"name": "Birinapant",
"lang": "EN"
}
]
] | null |
NCT03722108 | [
{
"id_field": "org_study_id",
"id_value": [
"UC-0110/1807"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2018-002374-46"
]
},
{
"id_field": "acronym",
"id_value": [
"REGIRI"
]
}
] | https://clinicaltrials.gov/study/NCT03722108 | Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas | Trial evaluating the efficacy of regorafenib combined with irinotecan compared to irinotecan alone in second-line treatment of patients with metastatic gastro-oesophageal adenocarcinomas. | A Randomised Phase 2 Trial Assessing REGorafenib Combined With IRInotecan as Second-line Treatment in Patients With Metastatic Gastro-oesophageal Adenocarcinomas | [
{
"description": "Irinotecan (180 mg/m² on D1 and D15 of a 4-week cycle) combined with regorafenib (160 mg daily on D2-8 and D16-22 of a 4-week cycle) administered until progression of disease or unacceptable toxicity",
"name": "Regorafenib and Irinotecan",
"normalized_type": "26823d77f12d4744a960c336f0... | [
{
"design_group_description": "Irinotecan 180 mg/m² on Day1 and Day 15 of a 4 week cycle combined with regorafenib 160 mg daily on Day2-8 and D16-22 of a 4 week cycle administered until progression of disease or unacceptable toxicity.",
"design_group_title": "Regorafenib and Irinotecan",
"design_group_t... | [
"Adenocarcinoma of the Stomach",
"Adenocarcinoma of the Gastroesophageal Junction"
] | [
"UNICANCER"
] | [
"Bayer AG"
] | [
[
{
"name": "瑞戈非尼",
"lang": "CN"
},
{
"name": "Regorafenib",
"lang": "EN"
},
{
"name": "レゴラフェニブ水和物",
"lang": "JP"
}
],
[
{
"name": "盐酸伊立替康",
"lang": "CN"
},
{
"name": "Irinotecan Hydrochloride",
"lang": "EN"
},
... | [
{
"identifier_source": [
{
"code": "8a299d55ee42eaea24a82d308a5e59e2",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "REGIRI - PRODIGE 58"
},
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
... |
NCT02572167 | [
{
"id_field": "org_study_id",
"id_value": [
"SGN35-025"
]
}
] | https://clinicaltrials.gov/study/NCT02572167 | A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma | The purpose of this study is to assess the safety profile and antitumor activity of brentuximab vedotin administered in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma (HL) | A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy | [
{
"description": "1.8 mg/kg by intravenous (IV) infusion for up to 4 cycles",
"name": "brentuximab vedotin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"SGN-35, ADCETRIS"
],
"type": "Drug"
},
{
"description": "3 mg/kg by intravenous (IV) infusion for... | [
{
"design_group_description": "Brentuximab vedotin plus nivolumab",
"design_group_title": "Brentuximab Vedotin + Nivolumab",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "... | [
"Hodgkin Lymphoma"
] | [
"Seagen, Inc."
] | [
"Bristol Myers Squibb Co."
] | [
[
{
"name": "纳武利尤单抗",
"lang": "CN"
},
{
"name": "Nivolumab",
"lang": "EN"
},
{
"name": "ニボルマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "维布妥昔单抗",
"lang": "CN"
},
{
"name": "Brentuximab Vedotin",
"lang": "EN"
},
... | [
{
"identifier_source": [
{
"code": "2ee3a5895e03a25ade2de8a8a50eee28",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "aaee2005ee850e9a454a30095239de5e",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "Pha... |
NCT07136285 | [
{
"id_field": "org_study_id",
"id_value": [
"Olvi-Vec-SCLC-202"
]
}
] | https://clinicaltrials.gov/study/NCT07136285 | Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC | Oncolytic virus product named Olvi-Vec combined with Platinum plus Etoposide in patients with late phase SCLC | PIb/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of I.V. Olvi-Vec Combined With Platinum Plus Etoposide in Patients With Advanced SCLC Who Are Platinum-recurrent or Platinum-refractory | [
{
"description": "Olvi-Vec will be administered to patient for 3 days during C1",
"name": "Olvi-Vec",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "After completing the first cycle of treatment of Olvi-Vec (+21 days after the last dose), Platinum ... | [
{
"design_group_description": "Olvi-Vec will be administered for 3 days in C1, then starting from C2, platinum (platinum (cisplatin or carboplatin)) and episode are administrated each 21 days till patients could not tolerate.",
"design_group_title": "Experimental",
"design_group_type": "Experimental",
... | [
"SCLC, Extensive Stage"
] | [
"Newsoara Biopharma (Shanghai) Co., Ltd."
] | [
"Genelux Corp."
] | [
[
{
"name": "依托泊苷",
"lang": "CN"
},
{
"name": "Etoposide",
"lang": "EN"
},
{
"name": "エトポシド",
"lang": "JP"
}
],
[
{
"name": "卡铂",
"lang": "CN"
},
{
"name": "Carboplatin",
"lang": "EN"
},
{
"name": "カルボプ... | [
{
"identifier_source": [
{
"code": "43e9822e0932292aaee838a5e8532a92",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "OLVI-VEC-SCLC-202"
}
] |
NCT07313605 | [
{
"id_field": "org_study_id",
"id_value": [
"127880"
]
},
{
"id_field": "acronym",
"id_value": [
"Epic-Beta"
]
},
{
"id_field": "secondary_id",
"id_value": [
"127880"
]
}
] | https://clinicaltrials.gov/study/NCT07313605 | POCUS-Guided Esmolol in Septic Shock: A Pilot RCT | The goal of this pilot clinical trial is to determine if conducting a larger study using point-of-care ultrasound (POCUS) to guide beta-blocker therapy in patients with septic shock is feasible. Septic shock is a life-threatening condition where infection causes dangerously low blood pressure, requiring medications to ... | Beta-Blocker Therapy Versus Standard Care in Patients With Septic Shock: A Pilot Randomized Controlled Trial Utilizing Predictive Enrichment With Point-of-Care Ultrasound | [
{
"description": "Patients will receive an intravenous infusion of esmolol, an ultra-short-acting cardioselective beta-1 adrenergic receptor antagonist with a half-life of approximately 9 minutes. The infusion will be titrated to achieve a target heart rate of 75-95 beats per minute, with a maximum dose of 300 ... | [
{
"design_group_description": "Patients randomized to this arm will receive standard care for septic shock according to Surviving Sepsis Campaign guidelines. This includes fluid resuscitation, a mean arterial pressure target of 65 mmHg or greater, early broad-spectrum antibiotics, source control when applicable... | [
"Septic Shock"
] | [
"University of Western Ontario"
] | [
"University of Western Ontario"
] | [
[
{
"name": "盐酸艾司洛尔",
"lang": "CN"
},
{
"name": "Esmolol Hydrochloride",
"lang": "EN"
},
{
"name": "エスモロール塩酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "Epic-Beta"
}
] |
NCT05357794 | [
{
"id_field": "org_study_id",
"id_value": [
"2021-0500"
]
},
{
"id_domain": "NCI-CTRP-Clinical Trial Reporting Registry",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"NCI-2022-03831"
]
},
{
"id_field": "secondary_id",
"id_value... | https://clinicaltrials.gov/study/NCT05357794 | Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides | To learn if a form of radiation therapy (called ultra-low-dose - total skin electron beam therapy [ULD-TSEBT]) in combination with brentuximab vedotin can help to control mycosis fungoides | Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides | [
{
"description": "Given by Vein (IV)",
"name": "Brentuximab vedotin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Adcetris",
"SGN-35"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Participant will receive radiation therapy to the entire skin surface over the course of 2 days. Each dose will take about 60 to 90 minutes and will vary from one patient to another",
"design_group_title": "Brentuximab vedotin",
"design_group_type": "Experimental",
"de... | [
"Mycosis Fungoides"
] | [
"The University of Texas MD Anderson Cancer Center"
] | [
"Pfizer Inc."
] | [
[
{
"name": "维布妥昔单抗",
"lang": "CN"
},
{
"name": "Brentuximab Vedotin",
"lang": "EN"
},
{
"name": "ブレンツキシマブ ベドチン（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT03915678 | [
{
"id_field": "org_study_id",
"id_value": [
"IB 2019-01"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2019-000850-78"
]
},
{
"id_field": "acronym",
"id_value": [
"AGADIR"
]
}
] | https://clinicaltrials.gov/study/NCT03915678 | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors | Basket trial concept to independently and simultaneously assess the effects of the association of atezolizumab + BDB001 + radiotherapy in multiple solid tumors. | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors | [
{
"description": "A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).<br/>BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be a... | [
{
"design_group_description": "Participants with pancreatic cancer will be treated with Atezolizumab combined with BDB001 and radiotherapy.",
"design_group_title": "Population 1: Pancreatic cancer",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61... | [
"Solid Tumor, Adult",
"Pancreatic Cancer",
"Virus-associated Tumors",
"Non Small Cell Lung Cancer",
"Melanoma",
"Bladder Cancer",
"Triple Negative Breast Cancer"
] | [
"Institut Bergonié"
] | [
"Eikon Therapeutics, Inc.",
"National Cancer Institute",
"Roche Pharma AG"
] | [
[
{
"name": "Resiquimod Sulfate",
"lang": "EN"
}
],
[
{
"name": "阿替利珠单抗",
"lang": "CN"
},
{
"name": "Atezolizumab",
"lang": "EN"
},
{
"name": "アテゾリズマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "482a292838eaa9a5d555dd20a9224285",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "AGADIR"
}
] |
NCT02489123 | [
{
"id_field": "org_study_id",
"id_value": [
"9340"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2015-00947"
]
},
{
"id_domain": "Fred Hutch/University of Washing... | https://clinicaltrials.gov/study/NCT02489123 | Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | This pilot clinical trial studies enzalutamide in treating patients with mantle cell lymphoma that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Androgens can cause the growth of cancer cells. Antihormone therapy, such as enzalutamide, may lessen the amou... | Androgen Receptor Targeting in Mantle Cell Lymphoma: A Pilot Trial of Enzalutamide | [
{
"description": "Given PO",
"name": "Enzalutamide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"ASP9785",
"MDV3100",
"Xtandi"
],
"type": "Drug"
},
{
"description": "Correlative studies",
"name": "Laboratory Biomarker Analysis",
"... | [
{
"design_group_description": "Patients receive enzalutamide PO QD. Courses 1-3 repeat every 4 weeks (28 days) and subsequent courses repeat every 12 weeks (84 days) in the absence of disease progression or unacceptable toxicity.",
"design_group_title": "Treatment (enzalutamide)",
"design_group_type": "... | [
"Ann Arbor Stage I Mantle Cell Lymphoma",
"Ann Arbor Stage II Mantle Cell Lymphoma",
"Ann Arbor Stage III Mantle Cell Lymphoma",
"Ann Arbor Stage IV Mantle Cell Lymphoma",
"Recurrent Mantle Cell Lymphoma",
"Refractory Mantle Cell Lymphoma"
] | [
"University of Washington"
] | [
"National Cancer Institute",
"National Comprehensive Cancer Network, Inc."
] | [
[
{
"name": "恩扎卢胺",
"lang": "CN"
},
{
"name": "Enzalutamide",
"lang": "EN"
},
{
"name": "エンザルタミド",
"lang": "JP"
}
]
] | null |
NCT05163106 | [
{
"id_field": "org_study_id",
"id_value": [
"2021/193780(REK)"
]
},
{
"id_field": "acronym",
"id_value": [
"NEOLETRIB"
]
}
] | https://clinicaltrials.gov/study/NCT05163106 | Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole | Patients with locally advanced (stage III) breast cancer (LABC) are characterized by a significantly worse prognosis compared to patients with primarily operable breast cancer. While neoadjuvant chemotherapy has been the first choice in this situation for several decades, recent evidence suggests that some patients may... | Presurgical Treatment With Ribociclib and Letrozole in Patients With Locally Advanced Breast Cancer: the NEOLETRIB Study. | [
{
"description": "Patients will be given letrozole 2.5mg and ribociclib 600mg daily, per oral for a period of 21 days followed by 7 days of letrozole only.",
"name": "Letrozole 2.5mg oral tablet; Ribociclib 600mg oral tablet",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
... | [
{
"design_group_description": "Patients entered into this study will be given letrozole (FemarTM) in combination with ribociclib (KisqaliTM) for at least 6 months. Premenopausal women will also receive treatment with goserelin 3.6 mg s.c. every 4 weeks.",
"design_group_title": "Ribociclib and Letrozole Arm"... | [
"Breast Cancer",
"HER2-negative Breast Cancer",
"ER-positive Breast Cancer",
"Locally Advanced Breast Cancer",
"Luminal A Breast Cancer",
"Luminal B Breast Cancer"
] | [
"Akershus Universitetssykehus HF"
] | [
"Novartis AG",
"Vestre Viken Hospital Trust"
] | [
[
{
"name": "来曲唑/琥珀酸瑞博西尼",
"lang": "CN"
},
{
"name": "Letrozole/Ribociclib Succinate",
"lang": "EN"
}
],
[
{
"name": "醋酸戈舍瑞林",
"lang": "CN"
},
{
"name": "Goserelin Acetate",
"lang": "EN"
},
{
"name": "ゴセレリン酢酸塩",
"lan... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "NEOLETRIB"
}
] |
NCT00743145 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB# 5693"
]
},
{
"id_domain": "National Institute on Drug Abuse (NIDA)",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number",
"id_value": [
"DA19239"
]
}
] | https://clinicaltrials.gov/study/NCT00743145 | Effects of Low-dose Naltrexone in Combination With a Range of Smoked Marijuana | In heavy marijuana smokers, opioid receptor blockade increases the subjective and cardiovascular effects of marijuana. The current study was designed to clarify opioid-cannabinoid interactions by assessing how naltrexone shifts the dose-response function for marijuana-elicited effects in heavy marijuana smokers. For th... | Effects of Low-dose Naltrexone in Combination With a Range of Smoked Marijuana | [
{
"description": "Marijuana cigarette containing 0% THC",
"name": "Inactive Marijuana (0% THC)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Cannabis"
],
"type": "Drug"
},
{
"description": "Marijuana cigarette containing 5.5% THC",
"name": "Activ... | [
{
"design_group_description": "Placebo naltrexone capsules (0mg), inactive marijuana (0% THC). Each study participant underwent 8 conditions in a randomized order.",
"design_group_title": "Placebo naltrexone + Inactive marijuana",
"design_group_type": "Placebo Comparator",
"design_group_type_normali... | [
"Marijuana Smoking"
] | [
"The New York State Psychiatric Institute"
] | [
"The Research Foundation for Mental Hygiene, Inc.",
"National Institute on Drug Abuse"
] | [
[
{
"name": "纳曲酮",
"lang": "CN"
},
{
"name": "Naltrexone",
"lang": "EN"
}
]
] | null |
NCT01974765 | [
{
"id_field": "org_study_id",
"id_value": [
"13-119"
]
}
] | https://clinicaltrials.gov/study/NCT01974765 | Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies | This is a Phase II study. The purpose of this study is to find out what effects, good and/or bad enzalutamide has on the patient and the cancer. All patients who enter the study will be closely monitored for side-effects. If multiple patients develop significant side effects from enzalutamide, the study may be stopped ... | A Phase II Trial of Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies | [
{
"description": "All enrolled patients will be treated with enzalutamide 160mg by mouth QD. Study drugs will be self-administered by patients. A cycle is 28 days.",
"name": "Enzalutamide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "After signing a screening consent, patients archival tissue will be evaluated for degree of AR positivity by AR staining. Patients with no archival tissue available will undergo a biopsy (using the modality deemed most appropriate by the patient's physician) for collection of tumo... | [
"Advanced Epithelial Ovarian",
"Recurrent Epithelial Ovarian",
"Fallopian Tube",
"Primary Peritoneal Carcinoma"
] | [
"Memorial Sloan Kettering Cancer Center"
] | [
"MediVation, Inc."
] | [
[
{
"name": "恩扎卢胺",
"lang": "CN"
},
{
"name": "Enzalutamide",
"lang": "EN"
},
{
"name": "エンザルタミド",
"lang": "JP"
}
]
] | null |
NCT02062658 | [
{
"id_field": "org_study_id",
"id_value": [
"#6811"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"K23MH092434"
]
}
] | https://clinicaltrials.gov/study/NCT02062658 | Extending Ketamine's Effects in OCD With Exposure and Response Prevention (EX/RP) | This study investigates if a single dose of IV Ketamine can rapidly improve Obsessive-Compulsive Disorder (OCD) symptoms and whether these effect can be maintained with a condensed course of a type of Cognitive Behavioral Therapy called Exposure and Response Prevention (EX/RP). You will be compensated for your time and... | Extending Ketamine's Effects in Obsessive-Compulsive Disorder (OCD) With Exposure and Response Prevention (EX/RP) | [
{
"description": "0.5mg/kg IV",
"name": "Ketamine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Ketamine hydrochloride"
],
"type": "Drug"
},
{
"description": "A type of Cognitive Behavioral Therapy called Exposure and Response Prevention.",
"name... | [
{
"design_group_description": "0.5mg/kg IV Ketamine infusion followed by condensed course of Exposure and Response Prevention (EX/RP)",
"design_group_title": "Ketamine, Exposure & Response Prevention",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22c... | [
"Obsessive-Compulsive Disorder"
] | [
"The New York State Psychiatric Institute"
] | [
"National Institute of Mental Health"
] | [
[
{
"name": "盐酸氯胺酮",
"lang": "CN"
},
{
"name": "Ketamine Hydrochloride",
"lang": "EN"
},
{
"name": "ケタミン塩酸塩",
"lang": "JP"
}
]
] | null |
NCT00003334 | [
{
"id_field": "org_study_id",
"id_value": [
"CDR0000066300"
]
},
{
"id_field": "secondary_id",
"id_value": [
"NYU-9708"
]
},
{
"id_field": "secondary_id",
"id_value": [
"NYGOG-NY9708"
]
},
{
"id_field": "secondary_id",
"id_value": [
"NC... | https://clinicaltrials.gov/study/NCT00003334 | Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.<br/>PURPOSE: Phase II trial to study the effectiveness of combining doxorubicin and paclitaxel in treating patients who have recurrent or refrac... | Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin | [
{
"name": "paclitaxel",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "pegylated liposomal doxorubicin hydrochloride",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"... | null | [
"Endometrial Cancer",
"Fallopian Tube Cancer",
"Ovarian Cancer",
"Sarcoma"
] | [
"NYU Langone Health"
] | [
"National Cancer Institute"
] | [
[
{
"name": "盐酸多柔比星脂质体",
"lang": "CN"
},
{
"name": "Doxorubicin Hydrochloride liposomal",
"lang": "EN"
}
],
[
{
"name": "紫杉醇",
"lang": "CN"
},
{
"name": "Paclitaxel",
"lang": "EN"
},
{
"name": "パクリタキセル",
"lang": "JP"... | null |
NCT00088998 | [
{
"id_field": "org_study_id",
"id_value": [
"NCCTG-N0432"
]
},
{
"id_domain": "CTRP (Clinical Trials Reporting System)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2012-02617"
]
},
{
"id_domain": "PDQ (Physician Data Query... | https://clinicaltrials.gov/study/NCT00088998 | Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer | RATIONALE: Drugs used in chemotherapy, such as docetaxel and capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as bevacizumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.... | Phase II Trial Of Docetaxel With Capecitabine And Bevacizumab As First-Line Chemotherapy For Patients With Metastatic Breast Cancer | [
{
"name": "bevacizumab",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"name": "capecitabine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "docetaxel",
"normalized_type": "3d1aa88261d64c038413723970f2b5... | [
{
"design_group_description": "Patients receive docetaxel IV over 1 hour and bevacizumab IV over 30-90 minutes on day 1. Patients also receive oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete re... | [
"Breast Cancer"
] | [
"Alliance Foundation Trials LLC"
] | [
"National Cancer Institute"
] | [
[
{
"name": "多西他赛",
"lang": "CN"
},
{
"name": "Docetaxel",
"lang": "EN"
},
{
"name": "ドセタキセル",
"lang": "JP"
}
],
[
{
"name": "贝伐珠单抗",
"lang": "CN"
},
{
"name": "Bevacizumab",
"lang": "EN"
},
{
"name": "... | [
{
"identifier_source": [
{
"code": "a02229492a23582de5022422d3389e0a",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "NCCTG N0432"
}
] |
NCT03844750 | [
{
"id_field": "org_study_id",
"id_value": [
"187015"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2018-03165"
]
}
] | https://clinicaltrials.gov/study/NCT03844750 | Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases | This phase II trials studies how well pembrolizumab and vactosertib work after standard of care chemotherapy in patients with colorectal cancer that has spread to the liver that can be removed by surgery (resectable hepatic metastases). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body'... | A Phase II Study of Preoperative Immunotherapy in Patients With Colorectal Cancer and Resectable Hepatic Metastases | [
{
"description": "Undergo liver resection.",
"name": "Hepatectomy",
"normalized_type": "a49da0f516744e0f8a08ffdea4946e99",
"other_name": [
"Liver Resection"
],
"type": "Procedure"
},
{
"description": "Given IV",
"name": "Pembrolizumab",
"normalized_type": "30faef638ae74... | [
{
"design_group_description": "Neoadjuvant pembrolizumab will be administered at a fixed dose of 200 mg (IV) for 1 cycle plus 200 mg vactosertib (PO QD, 5 days per week x 2 weeks). Adjuvant pembrolizumab (400 mg IV) + vactosertib (200 mg PO QD Cycle 1, 5 days per week, Cycles 2 and beyond (200 mg BID, 5 days pe... | [
"Metastatic Malignant Neoplasm in the Liver",
"Stage IV Colorectal Cancer AJCC v8",
"Stage IVA Colorectal Cancer AJCC v8",
"Stage IVB Colorectal Cancer AJCC v8",
"Stage IVC Colorectal Cancer AJCC v8"
] | [
"The University of California, San Francisco"
] | [
"MedPacto, Inc.",
"Merck Sharp & Dohme Corp."
] | [
[
{
"name": "帕博利珠单抗",
"lang": "CN"
},
{
"name": "Pembrolizumab",
"lang": "EN"
},
{
"name": "ペムブロリズマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "Vactosertib",
"lang": "EN"
}
]
] | null |
NCT05695378 | [
{
"id_field": "org_study_id",
"id_value": [
"KMCP-819-K102"
]
}
] | https://clinicaltrials.gov/study/NCT05695378 | Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy (MSA) | This trial will the efficacy of KM-819 compared to placebo in subjects with MSA for slowing the progression of MSA. | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy | [
{
"description": "Subjects will receive KM-819 400 mg orally daily.",
"name": "KM-819",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Subjects will receive Placebo orally daily.",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413... | [
{
"design_group_description": "Subjects will receive 400 mg of KM-819 orally from Week 0 to Week 36.",
"design_group_title": "Main Study: KM-819",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"interv... | [
"Multiple System Atrophy"
] | [
"Kainos Medicine, Inc."
] | [
"PAREXEL International Corp."
] | [
[
{
"name": "KM-819",
"lang": "EN"
}
]
] | null |
NCT05576480 | [
{
"id_field": "org_study_id",
"id_value": [
"SPARC"
]
},
{
"id_field": "acronym",
"id_value": [
"SPARC"
]
}
] | https://clinicaltrials.gov/study/NCT05576480 | SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer | The goal of this phase 2 study is to learn about the efficacy and safety of short-course radiotherapy (SCRT) sequential Penpulimab in combination with CAPEOX in the neoadjuvant treatment of microsatellite stable (MSS) locally advanced rectal cancer. The main question it aims to answer is the role of immune checkpoint i... | Efficacy and Safety of Short-course Radiotherapy Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of Microsatellite Stable Locally Advanced Rectal Cancer: a Single-centre, Single-arm, Phase 2 Study | [
{
"description": "5×5Gy in Week 1",
"name": "Short-course radiotherapy",
"normalized_type": "c030b727164e46bf9a75d711c55b9c57",
"type": "Radiation"
},
{
"description": "Apply once in the first week, then every 3 weeks from the third week for four cycles",
"name": "Penpulimab",
"norma... | [
{
"design_group_description": "* Short-course radiotherapy (SCRT) + one dose of immunotherapy in week 1：Radiotherapy once daily at 5Gy, D1-D5 (5×5Gy); Penpulimab, 200mg, intravenous for 60±5min, D6 or D7.<br/>* Rest at week 2, 4 cycles of chemotherapy (CAPEOX) + immunotherapy from week 3 in cycles of 3 weeks: C... | [
"Rectal Cancer",
"Locally Advanced"
] | [
"Ruijin Hospital"
] | [
"Chia Tai Tianqing Pharmaceutical Group Co., Ltd."
] | [
[
{
"name": "派安普利单抗",
"lang": "CN"
},
{
"name": "Penpulimab",
"lang": "EN"
}
],
[
{
"name": "奥沙利铂",
"lang": "CN"
},
{
"name": "Oxaliplatin",
"lang": "EN"
},
{
"name": "オキサリプラチン",
"lang": "JP"
}
],
[
{
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "SPARC"
}
] |
NCT02903446 | [
{
"id_field": "org_study_id",
"id_value": [
"F160315004"
]
}
] | https://clinicaltrials.gov/study/NCT02903446 | Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions | Bone erosions are a common manifestation and feature of structural damage in severe/chronic tophaceous gout. Management of this destructive and often debilitating gout complication has focused exclusively on urate-lowering therapy (ULT) to reduce frequency of gout attacks, but little attention has been given to prevent... | Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions in Gout: A Pilot Study | [
{
"description": "Participants will be randomized (1:1) allocation to denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + ULT standard of care OR ULT standard of care therapy",
"name": "Denosumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
... | [
{
"design_group_description": "Denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + urate lowering therapy (ULT) standard of care",
"design_group_title": "Intervention",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a7... | [
"Gout"
] | [
"The University of Alabama at Birmingham"
] | [
"Auckland University"
] | [
[
{
"name": "地舒单抗",
"lang": "CN"
},
{
"name": "Denosumab",
"lang": "EN"
},
{
"name": "デノスマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT04656951 | [
{
"id_field": "org_study_id",
"id_value": [
"Uni-Koeln-3946"
]
},
{
"id_field": "acronym",
"id_value": [
"GMMG-DADA"
]
},
{
"id_field": "secondary_id",
"id_value": [
"Uni-Koeln-3946"
]
}
] | https://clinicaltrials.gov/study/NCT04656951 | Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse | Daratumumab for first line treatment of transplant-ineligible myeloma patients followed by daratumumab re-treatment at first relapse (GMMG-DADA) | Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse | [
{
"description": "Daratumumab added to induction regimen of bortezomib, cyclophosphamide and dexamethasone (VCD), to bortezomib and dexamethasone during maintenance and to lenalidomide and dexamethasone at progression/relapse.",
"name": "Daratumumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b... | [
{
"design_group_description": "Daratumumab at standard dose of 1800 mg will be administered subcutaneously at weekly intervals in cycles 1-2 and every 2 weeks in cycles 3-6 and every 4 weeks in cycles 7-8 together with VCD using bortezomib weekly s.c. for 8 cycles of 28 days each, cyclophosphamide i.v. at 500 m... | [
"Multiple Myeloma"
] | [
"University of Cologne Executive School GmbH"
] | [
"Janssen-Cilag GmbH"
] | [
[
{
"name": "达雷妥尤单抗",
"lang": "CN"
},
{
"name": "Daratumumab",
"lang": "EN"
},
{
"name": "ダラツムマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "GMMG-DADA"
},
{
"identifier_source": [
{
"code": "d09402205a442a3d2e9a22202538a0a2",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
... |
NCT02024009 | [
{
"id_field": "org_study_id",
"id_value": [
"OCTO_063"
]
},
{
"id_field": "acronym",
"id_value": [
"SCALOP-2"
]
}
] | https://clinicaltrials.gov/study/NCT02024009 | Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2 | This study will evaluate the role of increasing radiotherapy dose and addition of nelfinavir to chemoradiotherapy (CRT) in patients with inoperable pancreatic cancer that has not spread beyond the pancreas.<br/>Currently in the United Kingdom (UK), either chemotherapy alone or chemotherapy followed by CRT can be used i... | A Multi-centre Randomised Study of Induction Chemotherapy Followed by Capecitabine (+/-Nelfinavir) With High or Standard Dose Radiotherapy for Locally Advanced Non-metastatic Pancreatic Cancer | [
{
"description": "Abraxane is a proprietary solvent-free, protein-stabilized formulation of paclitaxel comprised of paclitaxel and human albumin in a noncrystalline amorphous state",
"name": "nab-paclitaxel",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Abraxane"
... | [
{
"design_group_description": "12 weeks (3 cycles) of induction Gemcitabine and Nab-paclitaxel (GEMABX) chemotherapy then 1 cycle of GEMABX* whilst radiotherapy (RT) planned then capecitabine (830mg/m2 oral bd) + Nelfinavir** + 50.4 Grays (Gy) in 28# (arm A closed on 26Feb2020 due to lack of efficacy of nelfina... | [
"Pancreatic Neoplasms (Locally Advanced Non-metastatic)"
] | [
"University of Oxford"
] | [
"Celgene Corp.",
"Cancer Research UK"
] | [
[
{
"name": "白蛋白结合型紫杉醇",
"lang": "CN"
},
{
"name": "Albumin-Bound Paclitaxel",
"lang": "EN"
},
{
"name": "パクリタキセル(JAN)",
"lang": "JP"
}
],
[
{
"name": "盐酸吉西他滨",
"lang": "CN"
},
{
"name": "Gemcitabine Hydrochloride",
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "SCALOP-2"
}
] |
NCT03310632 | [
{
"id_field": "org_study_id",
"id_value": [
"GHPanc-1-001"
]
}
] | https://clinicaltrials.gov/study/NCT03310632 | Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer | Antroquinonol is proposed for the treatment of neoplasms. The proposed clinical trial is a Phase I/II study designed to evaluate antroquinonol in combination with nab-paclitaxel and gemcitabine in first line treatment naïve subjects with Stage IV metastatic pancreatic carcinoma. The first part of study will focus on th... | A Phase I/II Study to Determine the MTD and to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer | [
{
"description": "Antroquinonol: 100 mg and corn oil 100 mg encapsulated in a gelatin capsule administered orally. Dose will be selected(200mg TID or 300mg TID with SOC) after phase I, then follow up the best dose for 40 Patients for the efficacy.",
"name": "Antroquinonol",
"normalized_type": "3d1aa8826... | [
{
"design_group_description": "Antroquinonol will first be conducted by dose escalation(200mg TID and 300mgTID) to characterize the safety of antroquinonol in combination with the standard of care (SOC) (nab-paclitaxel + gemcitabine) and to identify the MTD of antroquinonol in patients with metastatic pancreati... | [
"Pancreatic Neoplasm"
] | [
"Golden Biotechnology Corporation"
] | [
"Labcorp Drug Development, Inc."
] | [
[
{
"name": "安卓奎诺尔",
"lang": "CN"
},
{
"name": "Antroquinonol",
"lang": "EN"
}
]
] | null |
NCT00855062 | [
{
"id_field": "org_study_id",
"id_value": [
"Uganda minocycline study"
]
},
{
"id_field": "secondary_id",
"id_value": [
"Grant Number: 5 UO1 NS32228"
]
}
] | https://clinicaltrials.gov/study/NCT00855062 | Minocycline for HIV+ Cognitive Impairment in Uganda | Purpose: The purpose of the study is to assess the safety and effectiveness of minocycline, an antibiotic, in the treatment of Human immunodeficiency virus (HIV)-associated cognitive impairment in Uganda.<br/>Study Design: Treatment, 24-week Randomized, Placebo-Controlled, Double-Blind Phase with Optional 24-week Open ... | Minocycline in the Treatment of HIV-Associated Cognitive Impairment in Uganda | [
{
"description": "100 mg capsule every 12 hours by mouth",
"name": "minocycline",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "1 capsule every 12 hours by mouth",
"name": "minocycline placebo capsule",
"normalized_type": "3d1aa88261d64c03... | [
{
"design_group_description": "Minocycline 100 mg orally every 12 hours",
"design_group_title": "Minocycline",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "100 mg ca... | [
"HIV-associated Cognitive Impairment",
"HIV Infections"
] | [
"The Johns Hopkins University"
] | [
"Makerere University"
] | [
[
{
"name": "盐酸米诺环素",
"lang": "CN"
},
{
"name": "Minocycline Hydrochloride",
"lang": "EN"
},
{
"name": "ミノサイクリン塩酸塩",
"lang": "JP"
}
]
] | null |
NCT03833206 | [
{
"id_field": "org_study_id",
"id_value": [
"ABV-1601-001"
]
}
] | https://clinicaltrials.gov/study/NCT03833206 | A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients | The purpose of this study is to evaluate the safety and the effective doses of PDC-1421 in cancer patients with depression. | A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients: Part I Dose Escalation | [
{
"description": "PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.",
"name": "PDC-1421 Capsule",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "1 PDC-1421 Capsule, trice daily, p.o. after meal for 28 days",
"design_group_title": "1 PDC-1421 Capsule",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_de... | [
"Major Depressive Disorder"
] | [
"BioLite, Inc."
] | [
"American BriVision Corp."
] | [
[
{
"name": "BLI-1008",
"lang": "EN"
}
]
] | null |
NCT04194554 | [
{
"id_field": "org_study_id",
"id_value": [
"UMCC 2019.117"
]
},
{
"id_domain": "University of Michigan",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"HUM00167325"
]
},
{
"id_field": "acronym",
"id_value": [
"ASCLEPIuS"
... | https://clinicaltrials.gov/study/NCT04194554 | A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer | The purpose of this study is to establish the maximum tolerable dose of niraparib when combined with prostate stereotactic body radiotherapy (SBRT), abiraterone, leuprolide, and prednisone (the phase 1 portion of the study) and determine 3-year biochemical PSA recurrence free-survival with this treatment approach (the ... | A Multi-Center Trial of Androgen Suppression With Abiraterone aCetate, LEuprolide, PARP Inhibition and Stereotactic Body Radiotherapy (ASCLEPIuS): A Phase I/2 Trial in High Risk and Node Positive Prostate Cancer | [
{
"description": "given PO per dose escalation schedule",
"name": "Niraparib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "22.5 mg q3 month",
"name": "Leuprolide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"... | [
{
"design_group_description": "Dose Level 1: 100 mg PO daily of Niraparib but held for 5 days (+/- 2 days) prior to RT, during SBRT, and 5 days (+/- 2 days) after last fraction of SBRT<br/>Dose Level 2: 200 mg PO daily of Niraparib but held for 5 days (+/- 2 days) prior to RT, during SBRT, and 5 days (+/- 2 day... | [
"Prostate Cancer"
] | [
"Rogel Cancer Center: University of Michigan"
] | [
"Janssen Scientific Affairs LLC"
] | [
[
{
"name": "醋酸阿比特龙",
"lang": "CN"
},
{
"name": "Abiraterone acetate",
"lang": "EN"
},
{
"name": "アビラテロン酢酸エステル",
"lang": "JP"
}
],
[
{
"name": "甲苯磺酸尼拉帕利",
"lang": "CN"
},
{
"name": "Niraparib Tosylate",
"lang": "EN"
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "2859592e8902a8849242235d95458e53",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "ASCLEPIuS"
}
] |
NCT04130698 | [
{
"id_field": "org_study_id",
"id_value": [
"1819-1483"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R15DA045917-01A1"
]
},
{
"id_field": "acronym",
"id_value": [
"BREATH"
]
}
] | https://clinicaltrials.gov/study/NCT04130698 | Comparing Two Treatments That Both Target Smoking Cessation and Weight Loss at the Same Time. | The study has two phases. In Phase 1, the investigators will revise and pilot the distress tolerance (DT) protocol that was originally developed and piloted in a previous study (2P20 GM103430, Spas, PI). Despite the 4-week post-intervention treatment outcomes demonstrating the DT protocol's association with smoking ces... | Biobehavioral Regulation to Extinguish Smoking While Treating Another Health Risk | [
{
"description": "The group-level intervention is comprised of one 2-hour weekly group sessions with overweight smokers to learn skills and strategies consistent with distress tolerance intervention to quit smoking and lose weight.",
"name": "Distress Tolerance",
"normalized_type": "f9cf04e7d3da41f2ae5e... | [
{
"design_group_description": "Treatment rationale: RAs will explain that there are 3 (not 2 as in the control) key factors that maintain smoking behavior and excess weight: 1) learned habits, 2) the addictive properties of smoking and food, and 3) a way to manage distress. Therefore, to be effective, an interv... | [
"Smoking Cessation",
"Weight Loss"
] | [
"Rhode Island College"
] | [
"National Institute on Drug Abuse"
] | [
[
{
"name": "尼古丁",
"lang": "CN"
},
{
"name": "Nicotine",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "BREATH"
}
] |
NCT01271504 | [
{
"id_field": "org_study_id",
"id_value": [
"E7050-701"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2011-000752-41"
]
}
] | https://clinicaltrials.gov/study/NCT01271504 | E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma | The purpose of this study is to determine whether patients with hepatocellular carcinoma who receive either E7050 administered with Sorafenib or Sorafenib alone experience greater benefit (cancer responds to treatment) when E7050 is administered with Sorafenib. | An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma | [
{
"description": "Phase Ib: Cohort 1; 200 mg E7050 + 400 mg Sorafenib Cohort 2; 300 mg E7050 + 400 mg Sorafenib Cohort 3; 400 mg E7050 + Sorafenib",
"name": "Sorafenib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "E7050 given orally at 200, 300 ... | [
{
"design_group_description": "Phase Ib: Cohort 1; 200 mg E7050 + 400 mg Sorafenib Cohort 2; 300 mg E7050 + 400 mg Sorafenib Cohort 3; 400 mg E7050 + Sorafenib",
"design_group_title": "Phase Ib: Cohort 1,2, and 3",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e7298... | [
"Hepatocellular Carcinoma"
] | [
"Eisai, Inc."
] | [
"PharmaBio Development, Inc."
] | [
[
{
"name": "甲苯磺酸索拉非尼",
"lang": "CN"
},
{
"name": "Sorafenib Tosylate",
"lang": "EN"
},
{
"name": "ソラフェニブトシル酸塩",
"lang": "JP"
}
]
] | null |
NCT03838042 | [
{
"id_field": "org_study_id",
"id_value": [
"Final4, 18-10-2023"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2018-000127-14"
]
},
{
"id_domain": "Sponsor's No",
"id_field": "secondary_id",
"id_type": "Other Identifier",
... | https://clinicaltrials.gov/study/NCT03838042 | INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies | The aim of this trial is to determine preliminary activity of the combination treatment with nivolumab and entinostat in children and adolescents with high risk refractory/relapsed/progressive tumors harboring a high mutational load, focal MYC(N) amplification or ATRT-MYC subgroup as well as tumors with high tumor infi... | INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies (INFORM2-NivEnt) | [
{
"description": "Patients entering phase I will receive one week entinostat without nivolumab (priming phase) before receiving the combination treatment of nivolumab and entinostat.",
"name": "Nivolumab and Entinostat",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"O... | [
{
"design_group_description": "Combination Study of Nivolumab and Entinostat",
"design_group_title": "Nivolumab and Entinostat",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description... | [
"CNS Tumor",
"Solid Tumor"
] | [
"University Hospital Heidelberg"
] | [
"German Cancer Research Center"
] | [
[
{
"name": "纳武利尤单抗",
"lang": "CN"
},
{
"name": "Nivolumab",
"lang": "EN"
},
{
"name": "ニボルマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT03222492 | [
{
"id_field": "org_study_id",
"id_value": [
"DAIT ITN075AI"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"UM1AI109565"
]
},
{
"id_domain": "DAIT NIAID",
"id_field": "secondary_id",
"id_type": "Other Identifier",
... | https://clinicaltrials.gov/study/NCT03222492 | Brentuximab Vedotin for Systemic Sclerosis | There is significant unmet need for effective treatment options for Diffuse Cutaneous Systemic Sclerosis (dcSSc). The present study will be a dose-escalation safety trial of brentuximab vedotin, a drug-antibody conjugate approved for the treatment of lymphoma and targeted to the protein CD30 molecule expressed on activ... | Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis BRAVOS: A Phase 1/2 Multicenter Randomized, Double Blinded, Safety Study (ITN075AI) | [
{
"description": "Ascending dose cohorts. All cohorts will receive intravenous administration of study medication every 3 weeks for 21 weeks, for a total of eight doses.",
"name": "Brentuximab Vedotin",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Adcetris®"
],
... | [
{
"design_group_description": "This is the first of three ascending dose cohorts. Participants in this cohort will receive 0.6 mg/kg brentuximab vedotin (to a maximum dose 60 mg) every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Brentuximab vedotin will be administered as an intraven... | [
"Diffuse Cutaneous Systemic Sclerosis",
"Scleroderma",
"dcSSc"
] | [
"National Institute of Allergy & Infectious Diseases"
] | [
"Pharmaceutical Product Development LLC",
"Immune Tolerance Network",
"Rho Federal Systems Division, Inc.",
"Seagen, Inc."
] | [
[
{
"name": "维布妥昔单抗",
"lang": "CN"
},
{
"name": "Brentuximab Vedotin",
"lang": "EN"
},
{
"name": "ブレンツキシマブ ベドチン（遺伝子組換え）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "5a555a382a0e89d9a4a04425a835a4e0",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "BRAVOS"
}
] |
NCT04669067 | [
{
"id_field": "org_study_id",
"id_value": [
"TL-895-203"
]
}
] | https://clinicaltrials.gov/study/NCT04669067 | TL-895 and KRT-232 Study in Acute Myeloid Leukemia | This study evaluates TL-895, a potent, orally available and highly selective irreversible tyrosine kinase inhibitor combined with navtemadlin (KRT-232), a novel oral small molecule inhibitor of MDM2 for the treatment of adults with FLT3 mutated Acute Myeloid Leukemia. Participants must be relapsed/refractory (e.g., hav... | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined With KRT-232 in Patients With Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML) | [
{
"description": "TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.",
"name": "TL-895",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.",
... | [
{
"design_group_description": "KRT-232 240mg QD, orally administered on days 1 through 7 of each 28-day cycle in combination with TL-895 150mg BID continuously for each 28-day cycle.",
"design_group_title": "Phase 1b - Dose Level 1",
"design_group_type": "Experimental",
"design_group_type_normalized... | [
"Acute Myeloid Leukemia"
] | [
"Telios Pharmaceuticals, Inc."
] | [
"Kartos Therapeutics, Inc."
] | [
[
{
"name": "Navtemadlin",
"lang": "EN"
}
],
[
{
"name": "M-7583",
"lang": "EN"
}
]
] | null |
NCT01980056 | [
{
"id_field": "org_study_id",
"id_value": [
"1305013919"
]
},
{
"id_domain": "Weill Cornell Medical College",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"IST/VOS/MDS"
]
}
] | https://clinicaltrials.gov/study/NCT01980056 | Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy | Study WCMC IST/VOS/MDS evaluates the safety and tolerability of escalating doses of vosaroxin in adult patients with pathologically confirmed Myelodysplastic Syndrome, or MDS, (< 20% blasts in bone marrow, peripheral blood, or both) by World Health Organization (WHO) classification with an intermediate 2 (INT-2) or hig... | A Phase 1/2, Open-label, Dose Escalation Clinical Study of the Safety and Clinical Activity of Vosaroxin in Patients With Intermediate 2 or High-risk Myelodysplastic Syndrome (MDS) After Failure of Hypomethylating Agent-based Therapy | [
{
"description": "Dose level 1: Vosaroxin 50 mg^m2 IV on Days 1 and 4 of 28 day cycle Dose level 2: Vosaroxin 72 mg^m2 IV on Days 1 and 4 of 28 day cycle Dose level 3: Vosaroxin 50 mg^m2 IV on Days 1, 4, 8 and 11 of 28 day cycle",
"name": "Vosaroxin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b... | [
{
"design_group_description": "All patients will receive vosaroxin according to the dose cohort in which they are enrolled.",
"design_group_title": "Vosaroxin: All Patients",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention... | [
"Myelodysplastic Syndrome"
] | [
"Weill Medical College of Cornell University"
] | [
"Sunesis Pharmaceuticals, Inc."
] | [
[
{
"name": "伏利拉辛",
"lang": "CN"
},
{
"name": "Vosaroxin",
"lang": "EN"
}
]
] | null |
NCT01578070 | [
{
"id_field": "org_study_id",
"id_value": [
"VSG-2011-101"
]
},
{
"id_field": "acronym",
"id_value": [
"VSG-2011-101"
]
}
] | https://clinicaltrials.gov/study/NCT01578070 | Single-center Study Evaluating the Safety and Efficacy of Viscogel® as Adjuvant in Act-HIB® Vaccine | The purpose of this study is to show that ViscoGel® is safe when administrated alone and as an adjuvant together with Act-HIB® vaccine in healthy volunteers and to evaluate the quantitative and qualitative effect on the immune response. | A Single-centre Study Evaluating the Safety of ViscoGel® and Its Safety and Efficacy as an Adjuvant in Act-HIB® Vaccine Administered by Intramuscular Injection to Healthy Volunteers in a Single-blind Randomised, Parallel-group Design | [
{
"description": "0.2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.",
"name": "0.2μg Act-HIB®",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "Pre-selected dose of ViscoGel® (from phase A) and Act-HIB® vaccine, IM (intramuscular... | [
{
"design_group_title": "ViscoGel® and 0.2μg Act-HIB®",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Pre-selected dose of ViscoGel® (from phase A) and Act-HIB® vaccine, IM (i... | [
"Healthy"
] | [
"Viscogel AB"
] | [
"Karolinska Institutet",
"Pharma Consulting Group AB"
] | [
[
{
"name": "b型流感嗜血杆菌结合疫苗(Sanofi)",
"lang": "CN"
},
{
"name": "Haemophilus b conjugate vaccine(Sanofi)",
"lang": "EN"
},
{
"name": "乾燥ヘモフィルス b 型ワクチン（破傷風トキソイド結合体）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "VSG-2011-101"
}
] |
NCT02885766 | [
{
"id_field": "org_study_id",
"id_value": [
"PF-114-01"
]
}
] | https://clinicaltrials.gov/study/NCT02885766 | Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene | A multicenter, open label cohort Phase 1 dose finding study to evaluate tolerability, safety, pharmacokinetics and preliminary efficacy of PF-114 for oral administration in adult patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML), which is resistant to the 2-nd generation Bcr-Abl inhibi... | A Multicenter, Open Label Cohort Phase 1 Dose Finding Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 Mesylate for Oral Administration in Adult Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML), Which is Resistant to the 2-nd Generation Bcr-A... | [
{
"name": "PF-114",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "PF-114 From 50 mg up to the MTD. Dose escalation for each next cohort is conducted by increasing the dose by 20 % (or the closest lower level, which is a multiple of 25 mg) if there are Grade 3 ADRs according to NCI CTC AE v.4 without reaching а MTD. An increase of the dose by 40 ... | [
"Chronic Myeloid Leukemia",
"Leukemia, Myelogenous, Chronic, BCR-ABL Positive"
] | [
"Fusion Pharmaceuticals, Inc."
] | [
"Data Matrix Solutions, Inc.",
"OCT Group LLC",
"Technopark Skolkovo LLC"
] | [
[
{
"name": "Vamotinib",
"lang": "EN"
}
]
] | null |
NCT05241145 | [
{
"id_field": "org_study_id",
"id_value": [
"IVNA 17-02"
]
}
] | https://clinicaltrials.gov/study/NCT05241145 | Safety and Preliminary Efficacy of IVMED-80 Eye Drops in Keratoconus Patients | We investigated the use of a copper sulfate eye drop (IVMED-80) for the treatment of keratoconus. Preliminary laboratory data shows that the addition of copper sulfate increase crosslinking of the structural proteins of the cornea thereby halting the progressing corneal thinning and bulging seen in keratoconus. We cond... | A Randomized, Controlled, Double-Masked Evaluation of the Safety and Preliminary Efficacy of IVMED-80 on Keratoconus Progression | [
{
"description": "Good Manufacturing Practices-grade copper (ІІ) sulfate pentahydrate (CuSO4 #5H2O MW 249.69) was dissolved in a vehicle solution comprised of a balanced salt solution (BSS) with osmolality of approximately 500 mOsm/L. Copper sulfate was concentrated to 0.15 mg/mL. The drops were manufactured on... | [
{
"design_group_description": "In Group 1 (IVMED-6Wk), patients instilled IVMED-80 eye drops into their study eye twice a day for 6 weeks and were followed for an additional 20 weeks without treatment (total 26 weeks)",
"design_group_title": "IVMED-6Wk",
"design_group_type": "Experimental",
"design_... | [
"Keratoconus",
"Corneal Ectasia"
] | [
"iVeena Delivery Systems, Inc."
] | [
"Codet Vision Institute"
] | [
[
{
"name": "IVMED-80",
"lang": "EN"
}
]
] | null |
NCT00004923 | [
{
"id_field": "org_study_id",
"id_value": [
"CDR0000067606"
]
},
{
"id_field": "secondary_id",
"id_value": [
"YALE-HIC-10023"
]
},
{
"id_field": "secondary_id",
"id_value": [
"NCI-G00-1700"
]
},
{
"id_field": "secondary_id",
"id_value": [
... | https://clinicaltrials.gov/study/NCT00004923 | Docetaxel and Irinotecan in Treating Patients With Advanced Solid Tumors | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.<br/>PURPOSE: Phase I/II trial to study the effectiveness of docetaxel and irinotecan in treating patients who have advanced solid tumors. | Dose Escalation Trial of Docetaxel Plus Irinotecan in Patients With Advanced Cancer | [
{
"name": "docetaxel",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "irinotecan hydrochloride",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Unspecified Adult Solid Tumor, Protocol Specific"
] | [
"Yale University"
] | [
"National Cancer Institute"
] | [
[
{
"name": "多西他赛",
"lang": "CN"
},
{
"name": "Docetaxel",
"lang": "EN"
},
{
"name": "ドセタキセル",
"lang": "JP"
}
],
[
{
"name": "盐酸伊立替康",
"lang": "CN"
},
{
"name": "Irinotecan Hydrochloride",
"lang": "EN"
},
{
... | null |
NCT01678898 | [
{
"id_field": "org_study_id",
"id_value": [
"PB-102-F01 & PB-102-F02"
]
},
{
"id_field": "nct_alias",
"id_value": [
"NCT01769001"
]
}
] | https://clinicaltrials.gov/study/NCT01678898 | Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients | This is the first human treatment with PRX-102, an enzyme being developed as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (alpha galactosidase deficiency). The safety, tolerability, and exploratory efficacy will be evaluated in this study of increasing doses. Patients w... | A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Months to Adult Fabry Patients | [
{
"name": "PRX-102",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"plant cell expressed recombinant human alpha-galactosidase-A"
],
"type": "Drug"
}
] | [
{
"design_group_description": "PRX-102 0.2 mg/kg every 2 weeks",
"design_group_title": "0.2 mg/kg",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_name": "PRX-102",
"intervention_... | [
"Fabry Disease"
] | [
"Protalix Biotherapeutics, Inc."
] | [
"CHIESI Farmaceutici SpA"
] | [
[
{
"name": "Pegunigalsidase alfa",
"lang": "EN"
}
]
] | null |
NCT05886205 | [
{
"id_field": "org_study_id",
"id_value": [
"K2153-K22C1488"
]
}
] | https://clinicaltrials.gov/study/NCT05886205 | Induced Pluripotent Stem Cell Derived Exosomes Nasal Drops for the Treatment of Refractory Focal Epilepsy | Evaluate the safety, tolerability, and preliminary efficacy of GD-iEXo-002 nasal drops in the treatment of focal refractory epilepsy | Exploratory Clinical Study on Induced Pluripotent Stem Cell Derived Exosomes (GD-iEXo-002) Nasal Drops for the Treatment of Refractory Focal Epilepsy | [
{
"description": "iPSC-Exos were administrated for nasal drip, bid for 12 weeks.",
"name": "iPSC-Exos",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | [
{
"design_group_description": "group1-low-dose group, 8 papatients are treated with 2 μg iPSC-Exos in 200 μL. group2-mid-dose group, 8 papatients are treated with 6 μg iPSC-Exos in 200 μL. group3-mid-dose group, 8 papatients are treated with 18 μg iPSC-Exos in 200 μL. group4-Dose expansion, 10 papatients are tr... | [
"Refractory Focal Epilepsy"
] | [
"Peking Union Medical College Hospital"
] | [
null
] | [
[
{
"name": "GD-iEXo-002",
"lang": "EN"
}
]
] | null |
NCT04870671 | [
{
"id_field": "org_study_id",
"id_value": [
"19-08-FB-0195"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"5R21AI145809-02"
]
}
] | https://clinicaltrials.gov/study/NCT04870671 | Project ADHERE: Clinical Proof-of-Concept of a Tenofovir (TFV) Aptamer-Based Biosensor | Truvada®, an oral pill comprised of two anti-retroviral compounds, emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF), is currently the only drug combination approved for pre-exposure prophylaxis (PrEP) in women exposed to high HIV risk through vaginal acquisition. Adherence to the one pill per day regimen is ... | Project ADHERE: Clinical Proof-of-Concept of a Tenofovir (TFV) Aptamer-Based Biosensor for Determining Adherence Using Different Dosing Regimens of Disoproxil Fumarate/Emtricitabine (TDF/FTC) | [
{
"description": "Women will take 1 pill orally according the dosing regimen of the arm to which they are assigned",
"name": "Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Truvada"
],
"type": "Drug"
}
] | [
{
"design_group_description": "TDF/FTC (300/200 mg), 7 pills/week. Total of 14 pills",
"design_group_title": "High Adherence",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description":... | [
"HIV/AIDS",
"Adherence, Medication",
"Drug Use"
] | [
"Eastern Virginia Medical School"
] | [
"National Institute of Allergy & Infectious Diseases"
] | [
[
{
"name": "恩曲他滨替诺福韦",
"lang": "CN"
},
{
"name": "Emtricitabine/Tenofovir Disoproxil Fumarate",
"lang": "EN"
},
{
"name": "エムトリシタビン/テノホビル ジソプロキシルフマル酸塩",
"lang": "JP"
}
]
] | null |
NCT04028245 | [
{
"id_field": "org_study_id",
"id_value": [
"AAAS2814"
]
},
{
"id_field": "acronym",
"id_value": [
"SPARC-1"
]
}
] | https://clinicaltrials.gov/study/NCT04028245 | A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma | Primary Objective:<br/>* To confirm the safety and feasibility of canakinumab and spartalizumab (PDR-001) administered using a standard dose / schedule in the neo-adjuvant setting in renal cell carcinoma<br/>Secondary Objectives:<br/>* To assess the immune response to combination canakinumab and spartalizumab<br/>* To ... | A Pilot Study of Neoadjuvant Combination Spartalizumab and Canakinumab Prior to Radical Nephrectomy in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1 Trial) | [
{
"description": "Spartalizumab at 400 mg weeks x 2 doses prior to radical nephrectomy Infusion",
"name": "Spartalizumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"PDR-001"
],
"type": "Drug"
},
{
"description": "Canakinumab 300 mg IV Q4 weeks x 2 ... | [
{
"design_group_description": "Subjects with renal cell carcinoma will receive study treatment Q4 weeks x 2 doses prior to radical nephrectomy.",
"design_group_title": "Spartalizumab and Canakinumab",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf... | [
"Carcinoma, Renal Cell"
] | [
"Columbia University"
] | [
"Novartis AG"
] | [
[
{
"name": "卡那奴单抗",
"lang": "CN"
},
{
"name": "Canakinumab",
"lang": "EN"
},
{
"name": "カナキヌマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "Spartalizumab",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "2005923a4a9e490aae4e82588982de85",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "SPARC-1"
}
] |
NCT00414570 | [
{
"id_field": "org_study_id",
"id_value": [
"DX-FLT-001"
]
}
] | https://clinicaltrials.gov/study/NCT00414570 | An Imaging Study of [18]F-fluoro-3'-Deoxy-3'-L-fluorothymidine ([18]F-FLT) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Who Will be Treated With Gemcitabine or Other Nucleoside Analogs | The objectives of this pilot study are: (i) to compare response to chemotherapy, time to disease progression and overall survival in patients with pancreatic cancer who will be treated with gemcitabine (or other nucleoside analogs) who demonstrate [18]F-FLT uptake to those patients who do not demonstrate [18]F-FLT upta... | null | [
{
"description": "Injection of [18]F-FLT radiopharmaceutical followed by PET imaging.",
"name": "[18]F-FLT PET scan",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"[18]F-FLT Positron Emission Tomography scan"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Radioactive dose of 2.59 MBq/kg (range 100 - 350 MBq) [18]F-FLT per injection prior to Positron Emission Tomography (PET) imaging. [18]F-FLT PET scans at baseline/pre-treatment and at disease progression, up to a maximum of two separate [18]F-FLT PET scans per participant.",
"... | [
"Pancreatic Cancer"
] | [
"AHS Cancer Control Alberta"
] | [
"Cross Cancer Institute"
] | [
[
{
"name": "Fluorothymidine F-18",
"lang": "EN"
}
]
] | null |
NCT05798507 | [
{
"id_field": "org_study_id",
"id_value": [
"STUDY00004876"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2023-00602"
]
},
{
"id_domain": "Emory University Hospit... | https://clinicaltrials.gov/study/NCT05798507 | Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma | This early phase I trial tests brain concentration level and safety of defactinib or VS-6766 for the treatment of patients with glioblastoma. Recently, two new drugs that seem to work together have been shown to have promising treatment effects in tissue culture and animal models of glioblastoma. Each inhibits a differ... | A Single-Dose Study of Orally Administrated Defactinib or VS-6766 in Patients With Glioblastoma | [
{
"description": "Given PO",
"name": "Avutometinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"CH-5126766",
"CH5126766",
"CKI-27",
"R-7304",
"RG 7304",
"RG-7304",
"RG7304",
"RO5126766",
"Raf/MEK Inhibitor VS-6766",
... | [
{
"design_group_description": "Patients receive 1 dose of defactinib PO while on study, prior to planned tumor resection. Patients undergo blood collection and donate resected tumor tissue while on study.",
"design_group_title": "Arm I (Defactinib)",
"design_group_type": "Experimental",
"design_grou... | [
"Glioblastoma",
"Recurrent Glioblastoma"
] | [
"Emory University"
] | [
"National Cancer Institute",
"Verastem, Inc."
] | [
[
{
"name": "阿伐替尼/地法替尼",
"lang": "CN"
},
{
"name": "Avutometinib/Defactinib",
"lang": "EN"
}
]
] | null |
NCT05555550 | [
{
"id_field": "org_study_id",
"id_value": [
"21-019390"
]
},
{
"id_domain": "CHOP",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"21NO104"
]
}
] | https://clinicaltrials.gov/study/NCT05555550 | Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG | The purpose of this study is to see if 18F-Fluciclovine (Axumin®) is useful and safe in the management of children with Low Grade Gliomas (LGG). Imaging with 18F-Fluciclovine PET-MRI will be performed prior to initiation of therapy for LGG, and then 3 months, and 1 year after starting therapy. Changes in 18F-Fluciclovi... | Evaluation of 18F-Fluciclovine PET-MRI as a Biomarker of Response in Pediatric and Young Adult Patients With Low Grade Gliomas (LGG) | [
{
"description": "18F-Fluciclovine will be injected via IV prior to PET-MRI imaging",
"name": "18F-Fluciclovine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Axumin"
],
"type": "Drug"
}
] | [
{
"design_group_description": "18F-Fluciclovine PET-MRI",
"design_group_title": "18F-Fluciclovine",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "18F-Fluciclovine will be ... | [
"Glioma",
"Low-grade Glioma",
"Low Grade Glioma of Brain",
"Glioma, Malignant",
"Glioma Intracranial"
] | [
"The Children's Hospital of Philadelphia"
] | [
"Blue Earth Diagnostics Ltd."
] | [
[
{
"name": "[18F]氟氨基丁酸",
"lang": "CN"
},
{
"name": "Fluciclovine 18F",
"lang": "EN"
},
{
"name": "フルシクロビン（18F）",
"lang": "JP"
}
]
] | null |
NCT01633762 | [
{
"id_field": "org_study_id",
"id_value": [
"ERA 2012"
]
},
{
"id_field": "acronym",
"id_value": [
"ERA"
]
}
] | https://clinicaltrials.gov/study/NCT01633762 | Eradication of Gut Microbiota | The aim of the study is to assess the effect of eradication of gut microbiota on 1) glucose metabolism including postprandial plasma responses of the incretin hormones GIP and GLP-1, insulin, C-peptide and glucagon, 2) metabolomic profiles and resting energy expenditure (REE) 3) appetite, satiety, food intake, gastric ... | Eradication of Gut Microbiota - Effects on Postprandial Gut Hormone Secretion, Glucose Metabolism, Bone Metabolism and Gut Microbiome | [
{
"description": "4 days antibiotic treatment, per oral, once daily: vancomycin 500 mg (Vancomycin \"Hospira\"), powder for concentrate; gentamycin 40 mg (\"Hexamycin®\"), solution; meropenem 500 mg (Meropenem \"Hospira\"), powder for concentrate; The three drugs are dissolved and combined to a cocktail (with a... | [
{
"design_group_title": "meropenem, gentamicin, vancomycin",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "4 days antibiotic treatment, per oral, once daily: vancomycin 500 mg... | [
"Diabetes",
"Obesity",
"Osteoporosis",
"Inflammation"
] | [
"Gentofte Hospital"
] | [
"University of Copenhagen",
"Rigshospitalet",
"Steno Diabetes Center A/S"
] | [
[
{
"name": "美洛培南",
"lang": "CN"
},
{
"name": "Meropenem",
"lang": "EN"
},
{
"name": "メロペネム水和物",
"lang": "JP"
}
],
[
{
"name": "硫酸庆大霉素",
"lang": "CN"
},
{
"name": "Gentamicin Sulfate",
"lang": "EN"
},
{
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ERA"
}
] |
NCT06735690 | [
{
"id_field": "org_study_id",
"id_value": [
"24431"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2024-10005"
]
},
{
"id_domain": "City of Hope Medical Center",
... | https://clinicaltrials.gov/study/NCT06735690 | Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia | This early phase I trial tests the safety and side effects of allogeneic CMV-specific CD19-CAR T cells plus CMV-MVA vaccine and how well it works in treating patients with high-risk acute lymphoblastic leukemia after a matched related donor (allogeneic) hematopoietic stem cell transplant (alloHSCT). Chimeric antigen re... | Pilot/Feasibility Study of CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Following Matched Related Allogeneic Hematopoietic Cell Transplantation for Patients With High-Risk Acute Lymphoblastic Leukemia | [
{
"description": "Undergo alloHSCT",
"name": "Allogeneic Hematopoietic Stem Cell Transplantation",
"normalized_type": "a49da0f516744e0f8a08ffdea4946e99",
"other_name": [
"Allogeneic",
"Allogeneic Hematopoietic Cell Transplantation",
"Allogeneic Stem Cell Transplantation",
"HS... | [
{
"design_group_description": "Patients receive HSCT conditioning regimen followed by alloHSCT per standard of care. Starting 28-49 days after alloHSCT, patients receive allo CMV-specific CD19-CAR T cells IV over 10-15 minutes on day 0. Patients undergo ECHO or MUGA, blood and optional CSF sample collection and... | [
"Acute Lymphoblastic Leukemia"
] | [
"City of Hope National Medical Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "Anti-CD19-CAR CMV-specific CAR-T(City of Hope Medical Center)",
"lang": "EN"
}
],
[
{
"name": "Multi-peptide CMV-Modified Vaccinia Ankara Vaccine(City of Hope National Medical Center)",
"lang": "EN"
}
]
] | null |
NCT01713218 | [
{
"id_field": "org_study_id",
"id_value": [
"2012-003516-31"
]
},
{
"id_field": "acronym",
"id_value": [
"NEOPACHI-001"
]
}
] | https://clinicaltrials.gov/study/NCT01713218 | Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer | Pancreatic ductal adenocarcinoma (PDAC) has one of the worst prognoses of all human cancers and is considered as a sanctuary, resistant to most of the drugs used. Identification of new molecular targets involved in its pathogenesis is urgently needed and required both proper and innovative efficacy assessment.<br/>This... | Evaluation of Tumoral Perfusion Modification by Dynamic Imaging After Neoadjuvant Chemotherapy Combining Gemcitabine and a Hedgehog Inhibitor (Vismodegib) in Patients With Resectable Pancreatic Adenocarcinoma | [
{
"description": "Administrated intravenously at a dose of 1000 mg/m2 over 30 minutes weekly, week 1 to 4",
"name": "gemcitabine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"GEMZAR"
],
"type": "Drug"
},
{
"description": "150 mg capsule, oral, once d... | [
{
"design_group_description": "Neoadjuvant chemotherapy combining gemcitabine and Vismodegib during 4 weeks before surgery",
"design_group_title": "Gemcitabine+Vismodegib",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention":... | [
"Pancreatic Adenocarcinoma Resectable"
] | [
"Hôpital Erasme"
] | [
"Roche Pharma AG"
] | [
[
{
"name": "盐酸吉西他滨",
"lang": "CN"
},
{
"name": "Gemcitabine Hydrochloride",
"lang": "EN"
},
{
"name": "ゲムシタビン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "维莫地吉",
"lang": "CN"
},
{
"name": "Vismodegib",
"lang": "EN"
}
]... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "NEOPACHI-001"
}
] |
NCT03660748 | [
{
"id_field": "org_study_id",
"id_value": [
"MET-3 101"
]
}
] | https://clinicaltrials.gov/study/NCT03660748 | Safety and Efficacy of MET-3 in Obese Human Subjects | A pilot study to explore the metabolic effect and safety of a 3-week course of therapy with MET-3 in obese subjects | A Phase I, Open-Label, Single-Centre Study of the Safety and Efficacy of Microbial Ecosystem Therapeutics (MET)-3 in Obese Human Subjects | [
{
"description": "Ingestion of a novel human microbiome preparation",
"name": "MET-2",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}
] | [
{
"design_group_description": "Use of MET-2 in subjects with BMI of 30.0 to 34.9",
"design_group_title": "Lower BMI",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Ingesti... | [
"Obesity"
] | [
"NuBiyota LLC"
] | [
"Glycemic Index Laboratories, Inc."
] | [
[
{
"name": "MET-2",
"lang": "EN"
}
]
] | null |
NCT00565201 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB00002727"
]
},
{
"id_field": "acronym",
"id_value": [
"Botox/Rehab"
]
}
] | https://clinicaltrials.gov/study/NCT00565201 | Evaluation of BOTOX® With Rehabilitation Therapy for the Treatment of Wrist and Hand Spasticity in Post-Stroke Patients | The present study is designed to determine the safety and effectiveness of injections of BOTOX® in spastic muscles of the arm and hand compared with injections of saline (which would do nothing) when combined with rehabilitation therapy for the improvement of active function tasks in post-stroke patients. Injections wi... | Evaluation of BOTOX® (Botulinum Toxin Type A) in Combination With Rehabilitation Therapy for the Treatment of Wrist and Hand Muscle Overactivity in Post-Stroke Patients | [
{
"description": "Patients will BOTOX® (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U ... | [
{
"design_group_description": "Patients will receive BOTOX® (100 to 360 U) injected into the any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Pronta... | [
"Stroke"
] | [
"Emory University"
] | [
"Allergan UC"
] | [
[
{
"name": "A型肉毒毒素",
"lang": "CN"
},
{
"name": "Onabotulinumtoxin A",
"lang": "EN"
},
{
"name": "A 型ボツリヌス毒素",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "Botox/Rehab"
}
] |
NCT07433517 | [
{
"id_field": "org_study_id",
"id_value": [
"VGN-Ex05e-001"
]
},
{
"id_field": "secondary_id",
"id_value": [
"VGN-Ex05e-001"
]
}
] | https://clinicaltrials.gov/study/NCT07433517 | VGN-Ex05e in Patients With Autism Spectrum Disorder Associated With Severe Self-Injurious and Aggressive Behaviors | To evaluate the safety and tolerability of intracerebral injection of VGN-Ex05e in the nucleus accumbens of patients with autism spectrum disorder. | An Early-Phase Clinical Study to Evaluate the Tolerability, Safety, and Efficacy of VGN-Ex05e in Patients With Autism Spectrum Disorder (ASD) Associated With Severe, Treatment-Resistant Self-Injurious and Aggressive Behaviors | [
{
"description": "Products derived from human embryonic stem cells for the treatment of allogeneic nerve cells",
"name": "VGN-Ex05e",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}
] | [
{
"design_group_description": "Stereotactic intracerebral injection of VGN-Ex05e solution into the nucleus accumbens with 2.0×10^6 cells or 6.0×10^6 cells.",
"design_group_title": "VGN-Ex05e",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",... | [
"Autism Spectrum Disorder"
] | [
"Shanghai Jiao Tong University School of Medicine"
] | [
"Shanghai Vitalgen Biopharma Co., Ltd."
] | [
[
{
"name": "VGN-Ex05e",
"lang": "EN"
}
]
] | null |
NCT05294367 | [
{
"id_field": "org_study_id",
"id_value": [
"LS200801"
]
},
{
"id_domain": "Mayo Clinic Institutional Review Board",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"21-005406"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NI... | https://clinicaltrials.gov/study/NCT05294367 | Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma | This early phase I trial investigates the effect of dietary and topical magnesium replacement on magnesium blood levels in patients with lymphoma. Magnesium is an element in the body that is important to cell health. The body cannot make magnesium and it typically comes from the food we eat. In patients who are ill, ma... | Pilot Feasibility Trial of Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma | [
{
"description": "Given topically",
"name": "Magnesium Chloride-based Lotion",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Ancient Minerals Magnesium Lotion",
"Magnesium Chloride Lotion"
],
"type": "Drug"
},
{
"description": "Ancillary studies"... | [
{
"design_group_description": "Participants consume magnesium rich foods PO daily for 28 days.",
"design_group_title": "Cycle 1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_descriptio... | [
"Lymphoma"
] | [
"Mayo Clinic"
] | [
"National Cancer Institute"
] | [
[
{
"name": "氯化镁",
"lang": "CN"
},
{
"name": "Magnesium chloride",
"lang": "EN"
}
]
] | null |
NCT07210632 | [
{
"id_field": "org_study_id",
"id_value": [
"VICCHN25046"
]
},
{
"id_field": "secondary_id",
"id_value": [
"VICCHN25046"
]
}
] | https://clinicaltrials.gov/study/NCT07210632 | Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG) | High-grade gliomas (HGGs) are among the most aggressive and treatment-resistant brain tumors. Immunotherapy with checkpoint inhibitors like nivolumab has shown promise, but its efficacy remains variable and poorly understood in this patient population. This clinical trial investigates a novel imaging-enabled formulatio... | Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG) | [
{
"description": "Participants will receive a single infusion of nivolumab following an infusion of nivolumab-IRDye800 (nivo800), for a combined total dose of 240 mg. This dosing applies to all cohorts except Cohort 1, which is designated as the safety group. Each cohort, other than Cohort 1, will receive no mo... | [
{
"design_group_description": "5mg nivo800",
"design_group_title": "Nivo800 (5mg)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Participants will receive an infusion of ... | [
"Brain Cancer",
"HGG",
"Glioma",
"High Grade Glioma",
"High Grade Gliomas",
"High Grade Glioma (III or IV)",
"High Grade Glioma (HGG) of the Brain With BRAF Aberration"
] | [
"The Vanderbilt-Ingram Cancer Center"
] | [
"The Vanderbilt-Ingram Cancer Center"
] | [
[
{
"name": "纳武利尤单抗",
"lang": "CN"
},
{
"name": "Nivolumab",
"lang": "EN"
},
{
"name": "ニボルマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT03159936 | [
{
"id_field": "org_study_id",
"id_value": [
"DLE"
]
}
] | https://clinicaltrials.gov/study/NCT03159936 | Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) | Evaluate the activity and safety of oral tofacitinib in adult patients with discoid lupus erythematosus with or without concurrent SLE. | Open Label Phase 2 Pilot Trial of Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) | [
{
"description": "10 mg daily by mouth",
"name": "Tofacitinib citrate",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Xeljanz"
],
"type": "Biological"
}
] | [
{
"design_group_description": "All participants will take one 5 mg tablet by mouth in the morning and one tablet by mouth in the evening for the 6-month study duration.",
"design_group_title": "Tofacitinib citrate",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562... | [
"Discoid Lupus Erythematosus",
"Systemic Lupus Erythematosus"
] | [
"Tufts Medical Center, Inc."
] | [
"Pfizer Inc."
] | [
[
{
"name": "枸橼酸托法替布",
"lang": "CN"
},
{
"name": "Tofacitinib Citrate",
"lang": "EN"
},
{
"name": "トファシチニブクエン酸塩",
"lang": "JP"
}
]
] | null |
NCT07457736 | [
{
"id_field": "org_study_id",
"id_value": [
"2000041030"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"2U01MH107803-06"
]
}
] | https://clinicaltrials.gov/study/NCT07457736 | Evaluation of [18F]GATT-44 for Positron Emission Tomography Imaging of the GABA Transporter-1 | Evaluate [18F]GATT-44 (aka [18F]GAT44), to characterize its pharmacokinetic, metabolic, and in vivo binding profile, and assess the reproducibility of kinetic and binding parameters. Assess specific binding levels of [18F]GATT-44 by conducting a test-block study in humans. Estimate human dosimetry of [18F]GATT-44 by pe... | Evaluation of [18F]GATT-44 for Positron Emission Tomography Imaging of the GABA Transporter-1 | [
{
"description": "First in human radiotracer being evaluated in this study.",
"name": "[ 18F]GATT-44",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"[18F]GAT44"
],
"type": "Drug"
}
] | [
{
"design_group_description": "In Part 1 we will conduct a test/retest study of the novel GABA Transporter (GAT-1) imaging tracer [18F]GATT44 in humans, to characterize its pharmacokinetic behavior and determine the reliability and reproducibility of in vivo pharmacokinetic parameter measurements",
"design_... | [
"Healthy Adult Participants"
] | [
"Yale University"
] | [
"National Institute of Mental Health"
] | [
[
{
"name": "[18F]GAT-44",
"lang": "EN"
}
]
] | null |
NCT03468140 | [
{
"id_field": "org_study_id",
"id_value": [
"2000021373"
]
}
] | https://clinicaltrials.gov/study/NCT03468140 | Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macrosteatotic Liver Transplantation | The number of liver transplants that can be performed is limited by the availability of organs. Livers that are steatotic (i.e., infiltrated by triglycerides and other fatty substances) are usually not used for transplants, due to increased risk of adverse events and deaths post-transplant. The investigators propose ad... | A Matched Intervention Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macrosteatotic Liver Transplantation | [
{
"description": "Eculizumab will be given at a dose of 1200mg diluted in 0.9% sodium chloride (NaCl) to 5mg/mL for a total volume of 240 mL administered by IV infusion over 25-45 minutes in the anhepatic-phase during the transplant procedure, and a second dose of 900mg diluted in 0.9% NaCl to 5mg/mL for a tota... | [
{
"design_group_description": "Eculizumab",
"design_group_title": "Current end stage liver disease patients",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Eculizumab will... | [
"End Stage Liver Disease"
] | [
"Yale University"
] | [
"Alexion Pharmaceuticals, Inc."
] | [
[
{
"name": "依库珠单抗生物类似药(Samsung Bioepis)",
"lang": "CN"
},
{
"name": "Eculizumab-AAGH",
"lang": "EN"
}
]
] | null |
NCT06494488 | [
{
"id_field": "org_study_id",
"id_value": [
"2133207"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"7R01HL159204-02"
]
}
] | https://clinicaltrials.gov/study/NCT06494488 | Differential Thrombogenesis by EPA and DHA Mediated by HDL | The goal of this study is to learn more about omega-3 polyunsaturated fatty acids supplementation on blood lipid profile and platelets in patients with high cholesterol levels.<br/>The purpose of this research is to gather information on the safety and effect of two different fish oils, eicosapentaenoic acid (EPA) and ... | Differential Thrombogenesis Effects of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) Mediated by High-Density Lipoprotein (HDL) | [
{
"description": "Fish oil",
"name": "EPA",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"eicosapentaenoic acid"
],
"type": "Drug"
},
{
"description": "Fish oil",
"name": "DHA",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_... | [
{
"design_group_description": "Participants will receive DHA supplement. 3 gelcaps, three times per day with meals (breakfast, lunch, and dinner). DHA supplement regimen contains 450 mg DHA and minimal EPA (60 mg) per pill.<br/>Participants will be given 28-day food and activity log.",
"design_group_title":... | [
"Lipid Metabolism Disorders",
"Hypertriglyceridemia"
] | [
"The Miriam Hospital"
] | [
"National Heart, Lung & Blood Institute",
"National Institutes of Health"
] | [
[
{
"name": "二十二碳六烯酸",
"lang": "CN"
},
{
"name": "Docosahexaenoic acid",
"lang": "EN"
}
],
[
{
"name": "二十碳五烯酸",
"lang": "CN"
},
{
"name": "Eicosapentaenoic acid",
"lang": "EN"
}
]
] | null |
NCT03566147 | [
{
"id_field": "org_study_id",
"id_value": [
"TR-RPE-RP/LCA"
]
}
] | https://clinicaltrials.gov/study/NCT03566147 | Treatment of RP and LCA by Primary RPE Transplantation | Early Phase I Study of the Safety and Preliminary Efficacy of Human primary Retinal Pigment Epithelial (HuRPE) Cells Subretinal Transplantation in Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) Patients | Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis by Primary Retinal Pigment Epithelial Cells Transplantation | [
{
"description": "HuRPE will be transplanted by a board-certified vitreoretinal surgeon, which will be administered into the subretinal space of experimental eye through a standard surgical approach.",
"name": "Human primary Retinal Pigment Epithelial (HuRPE) cells",
"normalized_type": "30faef638ae74cc7... | [
{
"design_group_description": "300,000 HuRPE cells",
"design_group_title": "low dose group",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "HuRPE will be transplanted by a ... | [
"Leber Congenital Amaurosis, Retinitis Pigmentosa"
] | [
"Jiangsu Aierkang Biomedical Technology Co., Ltd"
] | [
null
] | [
[
{
"name": "Human primary Retinal Pigment Epithelial (HuRPE) cells(Eyecure Therapeutics)",
"lang": "EN"
}
]
] | null |
NCT00895466 | [
{
"id_field": "org_study_id",
"id_value": [
"PEP223-NL-0701"
]
}
] | https://clinicaltrials.gov/study/NCT00895466 | Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients | The purpose of this trial is to investigate whether treatment with this new drug will result in lower testosterone levels in men with prostate cancer. At the same time it will be investigated whether the drug induces side effects, and if so, which ones. | A Phase I-II Open Label Clinical Trial, Evaluating the Efficacy and Safety of Administration of the Therapeutic Vaccine PEP-223/CoVaccine HT, to Hormone Treatment naïve, Immunocompetent Subjects With T1-3, N0-1/x, M0 Prostate Cancer, Eligible for Hormone Therapy. | [
{
"name": "PEP-223/CoVaccine HT",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"single_or_multi": "single_drug",
"type": "Biological"
}
] | null | [
"Prostate Cancer"
] | [
"Pepscan Therapeutics BV"
] | [
"TFS Trial Form Support AB"
] | [
[
{
"name": "PEP-223/CoVaccine HT(Pepscan Therapeutics)",
"lang": "EN"
}
]
] | null |
NCT00068718 | [
{
"id_field": "org_study_id",
"id_value": [
"1803.00"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2010-00163"
]
},
{
"id_domain": "Fred Hutchinson Cancer Resear... | https://clinicaltrials.gov/study/NCT00068718 | Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant | This phase I/II trial studies the side effects of donor lymphocyte infusion and to see how well it works in treating patients with persistent, relapsed (disease that has returned), or progressing cancer after donor hematopoietic cell transplantation. White blood cells from donors may be able to kill cancer cells in pat... | Donor Lymphocyte Infusion for the Treatment of Malignancy After Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning - A Multi-center Trial | [
{
"description": "Given IV",
"name": "Therapeutic Allogeneic Lymphocytes",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Allogeneic Lymphocytes"
],
"type": "Biological"
}
] | [
{
"design_group_description": "Patients undergo unirradiated DLI over 15-30 minutes on day 0. Patients then undergo restaging on day 28 and may undergo a second DLI after at least 4 weeks if no significant GVHD develops and disease status worsens or after at least 8 weeks if disease status is unchanged and pers... | [
"Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
"Recurrent Adult Acute Lymphoblastic Leukemia",
"Recurrent Adult Acute Myeloid Leukemia",
"Recurrent Hodgkin Lymphoma",
"Recurrent Non-Hodgkin Lymphoma",
"Recurrent Plasma Cell Myeloma"
] | [
"Fred Hutchinson Cancer Research Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "Allogeneic lymphocytes(Sidney Kimmel Cancer Center at Thomas Jefferson University)",
"lang": "EN"
}
]
] | null |
NCT00276406 | [
{
"id_field": "org_study_id",
"id_value": [
"05-004037"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"UL1RR024150-01"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"P0... | https://clinicaltrials.gov/study/NCT00276406 | Use of Pyridostigmine for Constipation in Diabetics | Doctors at Mayo Clinic are doing this study to learn if pyridostigmine, a drug, affects the speed at which food travels through the stomach, intestines and colon, and if pyridostigmine improves constipation symptoms in patients with diabetes. Pyridostigmine has been approved by the Food and Drug Administration (FDA) fo... | Pyridostigmine in Diabetics With Constipation: Randomized, Placebo-controlled, Double-blind Trial | [
{
"description": "Pyridostigmine will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.",
"name": "Pyridostigmine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Mestinon"
],
"type": "Drug"
},
{
"de... | [
{
"design_group_description": "Oral pyridostigmine, starting with 60 mg capsules three times per day (TID), increasing by 60 mg every third day (i.e., over 10 days) up to the maximum tolerated dose or 120 mg TID (a total of 360 mg per day). This dose was maintained for 7 days.",
"design_group_title": "Pyrid... | [
"Constipation",
"Diabetes Mellitus",
"Colonic Transit",
"Gastric Emptying"
] | [
"Mayo Clinic"
] | [
"National Institute of Diabetes & Digestive & Kidney Diseases",
"National Center for Research Resources"
] | [
[
{
"name": "溴吡斯的明",
"lang": "CN"
},
{
"name": "Pyridostigmine Bromide",
"lang": "EN"
},
{
"name": "ピリドスチグミン臭化物",
"lang": "JP"
}
]
] | null |
NCT05200442 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB21-2026"
]
}
] | https://clinicaltrials.gov/study/NCT05200442 | A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer | Doctors leading this study hope to learn about the safety of combining the study drug VS-6766 with another drug called cetuximab in colorectal cancer. This study is for individuals who have advanced colorectal cancer and their cancer has progressed while getting previous treatment or individuals who cannot take/tolerat... | A Phase 1b/2 Study of AVUTOMETINIB and Cetuximab in Participants With Advanced KRAS Mutated Colorectal Cancer | [
{
"description": "An oral anti-cancer medication.",
"name": "VS-6766/avutometinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "A chemotherapy drug used to treat head, neck and colorectal cancer.",
"name": "Cetuximab",
"normalized_type":... | [
{
"design_group_description": "This study will use two dose levels (a starting dose at level 1 and a second dose highest dose at level 2) of the VS-6766 and cetuximab regimen. If participants in group 1 don't experience severe negative side effects to the starting dose of the regimen, then more participants wil... | [
"Colorectal Cancer",
"Colorectal Adenocarcinoma",
"Colorectal Cancer Metastatic",
"Advanced Colorectal Carcinoma",
"Advanced Colorectal Adenocarcinoma"
] | [
"The University of Chicago"
] | [
"Verastem, Inc."
] | [
[
{
"name": "西妥昔单抗",
"lang": "CN"
},
{
"name": "Cetuximab",
"lang": "EN"
},
{
"name": "セツキシマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "Avutometinib",
"lang": "EN"
}
]
] | null |
NCT03161756 | [
{
"id_field": "org_study_id",
"id_value": [
"01.15"
]
},
{
"id_field": "acronym",
"id_value": [
"CHARLI"
]
}
] | https://clinicaltrials.gov/study/NCT03161756 | Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma | The purpose of this project is to test the addition of a new treatment called denosumab to standard immunotherapies for patients with metastatic melanoma. Denosumab has been used for many years to help treat cancers such as prostate cancer and breast cancer, but it is not currently used in melanoma. We hope the additio... | A Phase Ib/II Trial of Ipilimumab-Nivolumab-Denosumab and Nivolumab-Denosumab in Patients With Unresectable Stage III and IV Melanoma | [
{
"description": "Denosumab is a fully human monoclonal immunoglobulin type 2 (IgG2) antibody that binds with high affinity and specificity to RANK ligand (RANKL) and neutralises the activity of human RANKL, similar to the action of endogenous osteoprotegerin (OPG). Denosumab binding prevents the activation of ... | [
{
"design_group_description": "Patients in Arm A will receive nivolumab 3 mg/kg intravenously (IV) every 2 weeks for 4 doses and denosumab 120 mg subcutaneously (SC) given D1, D8, D15, D29 (induction phase). Thereafter, nivolumab 480 mg IV and denosumab 120 mg SC every 4 weeks for a total of 24 months (maintena... | [
"Melanoma Stage Iv",
"Melanoma Stage Iii",
"Melanoma"
] | [
"Melanoma & Skin Cancer Trials Ltd."
] | [
"Amgen, Inc.",
"Bristol Myers Squibb Co.",
"Peter MacCallum Cancer Institute"
] | [
[
{
"name": "伊匹木单抗",
"lang": "CN"
},
{
"name": "Ipilimumab",
"lang": "EN"
},
{
"name": "イピリムマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "纳武利尤单抗",
"lang": "CN"
},
{
"name": "Nivolumab",
"lang": "EN"
},
{
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "552ad820222aeeea85ee8a3325a32025",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "CHARLI"
}
] |
NCT04407247 | [
{
"id_field": "org_study_id",
"id_value": [
"2019-0276"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2019-04986"
]
},
{
"id_domain": "M D Anderson Cancer Center"... | https://clinicaltrials.gov/study/NCT04407247 | Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma | This phase I/II trial studies the side effects of infliximab and vedolizumab and to see how well they work in treating inflammation of the colon (colitis) caused by immune checkpoint inhibitor therapy in patients with cancer of the genital and urinary organs (genitourinary) or melanoma. Monoclonal antibodies, such as i... | Treatment of Immune Checkpoint Inhibitor-Related Colitis With Infliximab or Vedolizumab: A Randomized Trial | [
{
"description": "Given IV",
"name": "Infliximab",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Avakine",
"Remicade",
"Remsima",
"cA2"
],
"type": "Biological"
},
{
"description": "Given IV",
"name": "Vedolizumab",
"normalized... | [
{
"design_group_description": "Patients receive infliximab IV over 1 hour once at week 0, 2, 6 for a total of 3 doses in the absence of disease progression or unacceptable toxicity.",
"design_group_title": "Arm I (infliximab)",
"design_group_type": "Active Comparator",
"design_group_type_normalized_... | [
"Colitis",
"Lung Non-Small Cell Carcinoma",
"Malignant Genitourinary System Neoplasm",
"Malignant Solid Neoplasm",
"Melanoma"
] | [
"The University of Texas MD Anderson Cancer Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "维得利珠单抗",
"lang": "CN"
},
{
"name": "Vedolizumab",
"lang": "EN"
},
{
"name": "ベドリズマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT06683352 | [
{
"id_field": "org_study_id",
"id_value": [
"C5261023"
]
}
] | https://clinicaltrials.gov/study/NCT06683352 | A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People | This study is to learn about flu and COVID vaccines, either alone or when mixed together. Healthy people aged 18 or older can join. Participants will get one shot in each arm, either a flu or COVID vaccine, alone or mixed. The study lasts about 6 months, and participants need to visit the research site at least 3 times... | A PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID-19 IN HEALTHY INDIVIDUALS | [
{
"description": "Investigational Influenza Vaccine",
"name": "Investigational Influenza Vaccine",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "Pfizer-BioNTech COVID-19 Vaccine",
"name": "COVID-19 Vaccine",
"normalized_type": "30fae... | [
{
"design_group_description": "COVID-19 Vaccine (Dose 1) and Placebo",
"design_group_title": "Arm A",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Saline",
"inter... | [
"Influenza,Human",
"COVID-19"
] | [
"BioNTech SE"
] | [
"Pfizer Inc."
] | [
[
{
"name": "复必泰",
"lang": "CN"
},
{
"name": "Comirnaty-COVID-19 mRNA vaccine",
"lang": "EN"
},
{
"name": "トジナメラン",
"lang": "JP"
}
],
[
{
"name": "PF-07926307",
"lang": "EN"
}
]
] | null |
NCT00042224 | [
{
"id_field": "org_study_id",
"id_value": [
"R01MH060390"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01MH060390"
]
},
{
"id_domain": "NorthShore LIJ Health System",
"id_field": "secondary_id",
"id_type": "Other... | https://clinicaltrials.gov/study/NCT00042224 | Electroconvulsive Therapy in Clozapine Refractory Schizophrenia | This study will evaluate electroconvulsive therapy (ECT) in patients who have not responded adequately to clozapine. | ECT in Clozapine Refractory Schizophrenia | [
{
"description": "ECT will be used to augment clozapine in schizophrenic patients who continue to have psychotic symptoms despite optimal treatment with clozapine.",
"name": "Electroconvulsive Therapy (ECT)",
"normalized_type": "a49da0f516744e0f8a08ffdea4946e99",
"type": "Procedure"
},
{
"de... | [
{
"design_group_description": "Electroconvulsive therapy ECT plus clozapine for 8 weeks",
"design_group_title": "1 ECT plus clozapine",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_desc... | [
"Schizophrenia"
] | [
"Northwell Health, Inc."
] | [
"National Institute of Mental Health"
] | [
[
{
"name": "氯氮平",
"lang": "CN"
},
{
"name": "Clozapine",
"lang": "EN"
},
{
"name": "クロザピン",
"lang": "JP"
}
]
] | null |
NCT05597839 | [
{
"id_field": "org_study_id",
"id_value": [
"DF9001-001"
]
},
{
"id_domain": "Merck",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"KEYNOTE-F92"
]
},
{
"id_domain": "Merck",
"id_field": "secondary_id",
"id_type": "Other Iden... | https://clinicaltrials.gov/study/NCT05597839 | Study of DF9001 in Patients With Advanced Solid Tumors | DF9001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express epidermal growth fac... | A Phase 1/1b First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF9001 as a Monotherapy and in Combination Therapies in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in Selected Indica... | [
{
"description": "Immunotherapy agent targeting NK cells.",
"name": "DF9001",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Anti-PD-1 immunotherapy agent",
"name": "KEYTRUDA® (pembrolizumab)",
"normalized_type": "3d1aa88261d64c038413723970... | [
{
"design_group_description": "Dose escalation cohorts of DF9001 in sequential ascending order.",
"design_group_title": "Monotherapy DF9001 Dose Escalation",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Solid Tumor, Adult"
] | [
"Dragonfly Therapeutics, Inc."
] | [
"Merck Sharp & Dohme LLC"
] | [
[
{
"name": "DF-9001",
"lang": "EN"
}
],
[
{
"name": "帕博利珠单抗",
"lang": "CN"
},
{
"name": "Pembrolizumab",
"lang": "EN"
},
{
"name": "ペムブロリズマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT03417284 | [
{
"id_field": "org_study_id",
"id_value": [
"2017-0399"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2018-00906"
]
},
{
"id_domain": "M D Anderson Cancer Center"... | https://clinicaltrials.gov/study/NCT03417284 | Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation | This phase I/II trial studies the side effects and best dose of melphalan hydrochloride in treating participants with newly-diagnosed multiple myeloma who are undergoing a donor stem cell transplantation. Giving chemotherapy before a donor stem cell transplantation helps stop the growth of cells in the bone marrow, inc... | Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule(s) and Dose(s) of Melphalan for Injection (Evomela) as a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma | [
{
"description": "Undergo HSCT",
"name": "Autologous Hematopoietic Stem Cell Transplantation",
"normalized_type": "a49da0f516744e0f8a08ffdea4946e99",
"other_name": [
"AHSCT",
"Autologous Hematopoietic Cell Transplantation",
"Autologous Stem Cell Transplantation",
"Stem Cell T... | [
{
"design_group_description": "PREPARATIVE REGIMEN: Participants receive melphalan hydrochloride IV over 30-60 minutes on day -2.<br/>TRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes.<br/>POST-TRANSPLANT: Participants in both groups receive filgrasti... | [
"Plasma Cell Myeloma"
] | [
"The University of Texas MD Anderson Cancer Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "非格司亭(Sandoz International GmbH)",
"lang": "CN"
},
{
"name": "Filgrastim-SNDZ(Sandoz International Gmbh)",
"lang": "EN"
}
],
[
{
"name": "盐酸美法仑",
"lang": "CN"
},
{
"name": "Melphalan hydrochloride",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "308e42e02ee22a5ae245e820d50d2a0e",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "a3e2a40945e33de25995da24832ae0e2",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "ALC... |
NCT05491135 | [
{
"id_field": "org_study_id",
"id_value": [
"3571"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2019-000316-29"
]
},
{
"id_field": "acronym",
"id_value": [
"HELP"
]
}
] | https://clinicaltrials.gov/study/NCT05491135 | Hepatocyte Microbeads for Acute Liver Failure | Acute Liver Failure in children is associated with high mortality without liver transplantation. In addition, donor organ shortage makes it difficult to provide this treatment to every potential patient. Liver transplantation is life-saving but it carries the risk of major surgery and complications from lifelong anti-r... | Hepatocytes Co-Encapsulated With Mesenchymal Stromal Cells in Alginate Microbeads for the Treatment of Acute Liver Failure in Paediatric Patients (HELP) | [
{
"description": "The solution containing microbeads will be infused manually into the peritoneal cavity under ultrasound guidance, with usually a 50ml syringe, as a single infusion or several infusions, to achieve in excess of 25 million hepatocytes per kilogram of the body weight.",
"name": "HMB002",
... | [
{
"design_group_description": "All patients will receive HMB002 infusion into the peritoneal cavity.",
"design_group_title": "HMB002",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_descr... | [
"Acute Liver Failure"
] | [
"King's College Hospital NHS Foundation Trust"
] | [
"The Medical Research Council"
] | [
[
{
"name": "HMB002",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "HELP"
}
] |
NCT01380535 | [
{
"id_field": "org_study_id",
"id_value": [
"10-005"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2010-022780-35"
]
}
] | https://clinicaltrials.gov/study/NCT01380535 | Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD) | Chronic graft-versus-host disease (cGVHD) is a long-lasting complication that can occur after transplants. The transplanted cells seem to fight with the patient's own cells.<br/>Extracorporeal photopheresis (ECP) is a fairly new procedure for cGVHD. The participant gets a port to hook up to a machine. The machine remov... | A Randomized Controlled Study of Extracorporeal Photopheresis (ECP) Therapy With UVADEX for the Treatment of Patients With Moderate to Severe Chronic Graft-versus-Host Disease (cGvHD) | [
{
"description": "Methoxsalen delivered by ECP",
"name": "ECP Methoxsalen",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Extracorporeal photopheresis (ECP)",
"Uvadex"
],
"type": "Drug"
},
{
"description": "Tapered prednisone with cyclosporine or... | [
{
"design_group_description": "Participants receive methoxsalen administered via ECP in addition to standard of care",
"design_group_title": "ECP Methoxsalen + Standard of Care",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"interven... | [
"Chronic Graft Versus Host Disease"
] | [
"Keenova Therapeutics Plc"
] | [
"PAREXEL International Corp."
] | [
[
{
"name": "甲氧沙林",
"lang": "CN"
},
{
"name": "Methoxsalen",
"lang": "EN"
},
{
"name": "メトキサレン",
"lang": "JP"
}
]
] | null |
NCT01889147 | [
{
"id_field": "org_study_id",
"id_value": [
"CHDR1220"
]
}
] | https://clinicaltrials.gov/study/NCT01889147 | Microdose and First-In-Human (FIH) Study of Recombinant Human Placental Alkaline Phosphatase (hRESCAP) | In the present study human recombinant placental alkaline phosphatase (hRESCAP) will be investigated. Alkaline Phosphatase is naturally present in the body and reported to use lipopolysaccharde (LPS, bacterial endotoxins) and extracellular nucleotides leaking from damaged and ischemic cells as physiological substrates.... | A Single Dose Study to Assess the Peak Plasma Concentration of a Microdose of Recombinant Human Placental Alkaline Phosphatase (hRESCAP, Part 1) Followed by a Single Ascending Dose, FIH Study to Assess Safety and Tolerability of hRESCAP (Part 2). | [
{
"description": "one acute bolus administration of different dosages of hRESCAP (microdose, part 1; and FIH: low dose, 414 µg; medium dose, 2480 µg; high dose, 5300 µg; part 2)",
"name": "hRESCAP",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"recombinant human place... | [
{
"design_group_description": "Peak plasma concentration response of a dose hRESCAP will be examined and compared with the saline condition",
"design_group_title": "14C-hRESCAP",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"int... | [
"Healthy"
] | [
"Nederlandse Organisatie voor Toegepast-Natuurwetenschappelijk"
] | [
"Alloksys Life Sciences BV"
] | [
[
{
"name": "Recombinant human alkaline phosphatase(Alloksys Life Sciences BV)",
"lang": "EN"
}
]
] | null |
NCT05594017 | [
{
"id_field": "org_study_id",
"id_value": [
"STU 022018-005"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01NS125250"
]
}
] | https://clinicaltrials.gov/study/NCT05594017 | Pharmacological Modulation of Brain Oscillations in Memory Processing | The goal of this study is to learn about the effects of scopolamine (an anticholinergic drug) on areas of the brain involved in memory, and changes it may have on brain activity. The investigators will do this by testing epileptic patients who are already undergoing intracranial surgery for seizure monitoring, and meas... | Behavioral and Pharmacological Manipulation of Time Cell Activity in the Human Mesial Temporal Lobe | [
{
"description": "Patient receives a dose of scopolamine (0.4mg) via IV fifteen minutes prior to spatial or episodic memory task/completion.",
"name": "Scopolamine (0.4mg)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Patient receives a dose of ... | [
{
"design_group_description": "Subjects will receive a dose of scopolamine (0.4mg) on each day. Approximately 15 minutes after administration, the participant will then complete either an episodic or a spatial memory task session.<br/>If the patient completed the sham session already, this session will take pla... | [
"Epilepsy",
"Seizures",
"Cognitive Impairment, Mild",
"Memory Disorders",
"Memory Loss"
] | [
"The University of Texas Southwestern Medical Center"
] | [
"National Institute of Neurological Disorders & Stroke"
] | [
[
{
"name": "丁溴东莨菪碱",
"lang": "CN"
},
{
"name": "Scopolamine Butylbromide",
"lang": "EN"
},
{
"name": "ブチルスコポラミン臭化物",
"lang": "JP"
}
]
] | null |
NCT03255941 | [
{
"id_field": "org_study_id",
"id_value": [
"4798-CHS-ERC-17"
]
}
] | https://clinicaltrials.gov/study/NCT03255941 | Clinical Study of Depo Provera Comparing Lay Health Workers and Clinically-trained Health Workers | This is a randomized controlled trial comparing lay Lady Health Workers (Lay Health Workers) with Family Welfare Workers (Clinically- trained Health Workers) on quantitative measures of safety and effectiveness of Depo Provera and Sayana Press provision in a clinic setting. This comparative trial will test the non-infe... | 'A Randomized Controlled Trial of Safety and Effectiveness of Depo Provera Intramuscular and Subcutaneous Administration Comparing Lay Lady Health Workers With Clinically-trained Family Welfare Workers in Pakistan | [
{
"description": "The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use DMPA.",
"name": "DMPA",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "The s... | [
{
"design_group_description": "Urban Clinic Provider providing DMPA or Sayana Press",
"design_group_title": "Clinic Provider - Urban",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_... | [
"Contraception"
] | [
"FHI 360, Inc."
] | [
"Aga Khan University",
"Province of Sindh",
"Jhpiego Corp."
] | [
[
{
"name": "醋酸甲羟孕酮",
"lang": "CN"
},
{
"name": "Medroxyprogesterone Acetate",
"lang": "EN"
},
{
"name": "メドロキシプロゲステロン酢酸エステル",
"lang": "JP"
}
]
] | null |
NCT03591757 | [
{
"id_field": "org_study_id",
"id_value": [
"H-37757"
]
}
] | https://clinicaltrials.gov/study/NCT03591757 | Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR) | The purpose of this study is to determine whether Tolcapone crosses from the blood stream into the fluid around the brain and stabilizes the protein that makes leptomeningeal amyloid. Tolcapone is a commercially available generic drug that treats Parkinson's disease.<br/>The Investigator plans to evaluate Tolcapone as ... | An Open-Label, Investigator Study to Evaluate the Short-term (4 Weeks) Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR) With and Without CNS Manifestations | [
{
"description": "Tolcapone will be administered at 300 mg/day (100mg TID) orally to participants for 14 days and then 600 mg/day (200 mg TID) orally to participants for 14 days (approximately 5 hours apart). Participants will initiate 200mg TID after blood collection on Day 14.",
"name": "Tolcapone",
"... | [
{
"design_group_description": "Tolcapone will be administered to assess the short-term (4 weeks) effects on plasma and CSF TTR tetramer stability in subjects with TTR CNS Amyloidosis. Tolcapone is currently licensed for the treatment of Parkinson's disease in combination with levodopa/carbidopa. It is an immedi... | [
"Transthyretin Amyloidosis",
"Amyloidosis, Leptomeningeal, Transthyretin-Related"
] | [
"Boston University"
] | [
"Corino Therapeutics, Inc."
] | [
[
{
"name": "托卡朋",
"lang": "CN"
},
{
"name": "Tolcapone",
"lang": "EN"
}
]
] | null |
NCT02929797 | [
{
"id_field": "org_study_id",
"id_value": [
"CD8+NKG2D+ AKT"
]
},
{
"id_field": "acronym",
"id_value": [
"AKT"
]
}
] | https://clinicaltrials.gov/study/NCT02929797 | Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer | A Prospective Study on the Efficacy and Safety of CD8+NKG2D+ AKT cell immunotherapy to the pancreatic cancer patients treated with adjuvant chemotherapy. | A Randomized, Double Blinding, Placebo-Controlled Clinical Trials of CD8+NKG2D+ AKT Cell Immunotherapy to the Pancreatic Cancer Patients Treated With Adjuvant Chemotherapy | [
{
"description": "AKT: CD8+NKG2D+ AKT cell",
"name": "CD8+NKG2D+ AKT Cell",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"AKT"
],
"type": "Biological"
},
{
"description": "gemcitabine",
"name": "Gemcitabine",
"normalized_type": "3d1aa88261d64c0... | [
{
"design_group_description": "gemcitabine dose 1000mg/M^2, d1,8,15，q4w ×6 AKT 5*10^8/M^2, d16,q4w ×6 Drug: gemcitabine Biological: AKT, CD8+NKG2D+ AKT Cell",
"design_group_title": "AKT + gemcitabine",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22c... | [
"Pancreatic Ductal Adenocarcinoma"
] | [
"Shanghai First People's Hospital"
] | [
"Shanghai Saiao Biotechnology Co. Ltd."
] | [
[
{
"name": "CD8+NKG2D+ AKT cell(Shanghai iCELL Biotechnology)",
"lang": "EN"
}
],
[
{
"name": "盐酸吉西他滨",
"lang": "CN"
},
{
"name": "Gemcitabine Hydrochloride",
"lang": "EN"
},
{
"name": "ゲムシタビン塩酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "CD8+NKG2D+ AKT"
},
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "AKT"
}
] |
NCT05665465 | [
{
"id_field": "org_study_id",
"id_value": [
"Pro00110997"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1R01DA054972-01A1"
]
}
] | https://clinicaltrials.gov/study/NCT05665465 | Neurobehavioral Mechanisms Linking Childhood Adversity to Increased Risk for Smoking | The purpose of this study is to evaluate how certain childhood experiences influences brain function and responses to nicotine exposure in a group of nonsmoking young adults. The investigators assess responses to nicotine exposure by giving participants a small amount of nicotine or placebo, and then asking them to ans... | Neurobehavioral Mechanisms Linking Childhood Adversity to Increased Risk for Smoking | [
{
"description": "Participants will be administered nicotine nasal spray and provide subjective reactions",
"name": "Nicotine nasal spray 0.5 mg",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Nicotrol"
],
"type": "Drug"
},
{
"description": "Participan... | [
{
"design_group_description": "Participants will be administered 2 nasal sprays with a combined nicotine content of 0mg nicotine, 0.1mL",
"design_group_title": "Placebo",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"interventi... | [
"Adverse Childhood Experiences",
"Nicotine Dependence, Cigarettes"
] | [
"Duke University"
] | [
"National Institute on Drug Abuse"
] | [
[
{
"name": "尼古丁",
"lang": "CN"
},
{
"name": "Nicotine",
"lang": "EN"
}
]
] | null |
NCT06407947 | [
{
"id_field": "org_study_id",
"id_value": [
"CT071-CG7002"
]
}
] | https://clinicaltrials.gov/study/NCT06407947 | Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma | This trial is a single-arm, single-center, open-label clinical trial to evaluate the safety, efficacy, and metabolism kinetics of CT071 in patients with high-risk newly diagnosed multiple myeloma. | Exploratory Clinical Trial of the Safety and Efficacy of CT071 Injection in Patients With High Risk Newly Diagnosed Multiple Myeloma | [
{
"description": "chimeric antigen receptor T cells",
"name": "Chimeric antigen receptor modified T cells Infusion",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Single Group Assignment"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Chimeric antigen receptor modified T cells chimeric antigen receptor T cells",
"design_group_title": "Chimeric antigen receptor modified T cells Infusion",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"... | [
"Multiple Myeloma"
] | [
"Shanghai Changzheng Hospital"
] | [
"CARsgen Therapeutics Co. Ltd."
] | [
[
{
"name": "CT-071",
"lang": "EN"
}
]
] | null |
NCT06464367 | [
{
"id_field": "org_study_id",
"id_value": [
"2000034634"
]
},
{
"id_domain": "VA Connecticut Healthcare System",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"ES0006"
]
}
] | https://clinicaltrials.gov/study/NCT06464367 | Mechanistic Studies of Psilocybin in Headache Disorders | In previous clinical trial work, the investigators observed lasting reductions in headache burden after limited dosing of psilocybin. This purpose of this study is to examine potential sources for this observed effect. This study will measure brain resting state functional connectivity (fMRI), central synaptic density ... | Mechanistic Studies of Psilocybin in Headache Disorders | [
{
"description": "synthetic psilocybin 10 mg (oral)",
"name": "Psilocybin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "synthetic THC 2.5 mg (oral)",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "... | [
{
"design_group_description": "Migraine participants randomized to receive 10 mg psilocybin (oral)",
"design_group_title": "Migraine psilocybin",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"interve... | [
"Migraine"
] | [
"Yale University"
] | [
"The Wallace Foundation"
] | [
[
{
"name": "裸盖菇素",
"lang": "CN"
},
{
"name": "Psilocybin",
"lang": "EN"
}
]
] | null |
NCT00795457 | [
{
"id_field": "org_study_id",
"id_value": [
"07-057"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R21CA133859-01A1"
]
}
] | https://clinicaltrials.gov/study/NCT00795457 | Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas | This is a pilot vaccine study in adults with either WHO grade II astrocytoma, oligoastrocytoma or oligodendroglioma. The purpose of this study is test the safety and efficacy of an experimental tumor vaccine made from peptides and Montanide ISA-51 in combination with the study drug Poly-ICLC.<br/>Poly-ICLC, manufacture... | A Bi-Institutional Pilot Study to Evaluate the Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With WHO Grade II Low-Grade Gliomas | [
{
"description": "Participants will be treated with subcutaneous injections of GAA/TT-vaccines on Weeks 0, 3, 6, 9, 12, 15, 18 and 21. I.m. poly-ICLC will be administered (20 mg/kg i.m.) on the day of, and on day 4 after each vaccine (e.g. if the vaccine is administered on Thursday, poly-ICLC will be administer... | [
{
"design_group_description": "Patients must have undergone surgery or biopsy alone ≤16 weeks prior to study entry (no postoperative radiation or chemotherapy).",
"design_group_title": "1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
... | [
"Astrocytoma",
"Oligo-Astrocytoma",
"Glioma"
] | [
"University of Pittsburgh"
] | [
"Oncovir, Inc.",
"National Cancer Institute"
] | [
[
{
"name": "聚肌胞",
"lang": "CN"
},
{
"name": "Poly ICLC",
"lang": "EN"
}
]
] | null |
NCT03349606 | [
{
"id_field": "org_study_id",
"id_value": [
"PRO10030625"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01DA026472"
]
},
{
"id_domain": "University of Pittsburgh",
"id_field": "secondary_id",
"id_type": "Other Ide... | https://clinicaltrials.gov/study/NCT03349606 | Cocaine Use Disorder and Cortical Dopamine | The goal of this study is to use [C-11]FLB 457 and amphetamine (oral, 0.5 mg/kg) to measure cortical dopamine transmission in cocaine dependent individuals and healthy controls | Imaging of Cortical Dopamine Transmission in Cocaine Dependence | [
{
"description": "oral d- amphetamine 0.5 mg/kg is used to stimulate dopamine release in the brain",
"name": "d-amphetamine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "PET radiotracer",
"name": "[C-11]FLB 457",
"normalized_type": "c030... | [
{
"design_group_description": "[C-11]FLB 457 PET at baseline and post d-amphetamine",
"design_group_title": "Cocaine dependence",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_descriptio... | [
"Cocaine Dependence"
] | [
"University of Pittsburgh"
] | [
"National Institute on Drug Abuse"
] | [
[
{
"name": "右旋安非他明",
"lang": "CN"
},
{
"name": "Dextroamphetamine",
"lang": "EN"
}
]
] | null |
NCT05011760 | [
{
"id_field": "org_study_id",
"id_value": [
"STUDY20060171 (Aim 2)"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01DA026472"
]
}
] | https://clinicaltrials.gov/study/NCT05011760 | [C-11]NPA PET-amphetamine in Cocaine Use Disorders | This study uses [11C]NPA positron emission tomography (PET) and a d-amphetamine challenge to image amphetamine induced dopamine release in the striatum in subjects with cocaine use disorders (CUD). Amphetamine-induced dopamine release data from this study will be correlated with [11C]NOP-1A VT measured at baseline in t... | [C-11]NPA PET-amphetamine in Cocaine Use Disorders (Aim 2) | [
{
"description": "Radiotracer",
"name": "Baseline [C-11]NPA PET Scan",
"normalized_type": "c030b727164e46bf9a75d711c55b9c57",
"type": "Radiation"
},
{
"description": "Oral, 0.5 mg/Kg",
"name": "d-amphetamine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
... | [
{
"design_group_description": "[C-11]NPA PET Scan",
"design_group_title": "PET",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Oral, 0.5 mg/Kg",
"intervention_name... | [
"Cocaine Use Disorder"
] | [
"University of Pittsburgh"
] | [
"National Institute on Drug Abuse"
] | [
[
{
"name": "右旋安非他明",
"lang": "CN"
},
{
"name": "Dextroamphetamine",
"lang": "EN"
}
]
] | null |
NCT03965546 | [
{
"id_field": "org_study_id",
"id_value": [
"2019（ZD13）"
]
}
] | https://clinicaltrials.gov/study/NCT03965546 | ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer | The purpose of this study is to evaluate the efficacy and safety of ET 140202 -T cell combined With TAE or Sorafenib in the treatment of liver cancer | Clinical Study of ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Advanced Liver Cancer | [
{
"description": "1. Sorafenib starting dose of 400mg b.i.d. a.c.<br/>2. Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) expression construct by intravenous (IV) infusion",
"name": "Sorafenib combined with ET140202-T cell",
"normalized_type": "26823d77f12d4744a960c336f01c2d... | [
{
"design_group_description": "Sorafenib treatment everyday and autologous ET140202-T cell administered by intravenous (IV) infusion",
"design_group_title": "ET140202-T cell combine with Sorafenib",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61... | [
"Hepatocellular Carcinoma",
"Liver Cancer",
"Liver Neoplasms",
"Metastatic Liver Cancer"
] | [
"First Affiliated Hospital of Xi'an Jiaotong University"
] | [
"Eureka Therapeutics, Inc."
] | [
[
{
"name": "ET1402L1-CART",
"lang": "EN"
}
],
[
{
"name": "甲苯磺酸索拉非尼",
"lang": "CN"
},
{
"name": "Sorafenib Tosylate",
"lang": "EN"
},
{
"name": "ソラフェニブトシル酸塩",
"lang": "JP"
}
]
] | null |
NCT04982354 | [
{
"id_field": "org_study_id",
"id_value": [
"2019-KOE-003"
]
}
] | https://clinicaltrials.gov/study/NCT04982354 | Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia | This is a pilot study designed to identify the effect of daunorubicin-cytarabine liposome (CPX-351) in combination with a FLT3-inhibitor (midostaurin) as induction and consolidation therapy for patients with high-risk FLT3 mutated acute myeloid leukemia (AML) and subsequent CD34+-selected allogeneic stem cell transplan... | A Pilot Study of Daunorubicin-cytarabine Liposome (CPX-351) Plus FLT3-inhibitor (Midostaurin) as Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia Followed by Consolidation With a CD34+-Selected Allograft | [
{
"description": "For this trial, patients will be treated with CPX-351 100 (daunorubicin 44 mg/m2 and cytarabine 100 mg/m2) for 3 doses on days 1, 3 and 5 of one and on days 1 + 3 of a second cycle of induction therapy, depending on response obtained following the first induction. Thereafter, up to 2 cycles of... | [
{
"design_group_description": "Daunorubicin-cytarabine liposome (CPX-351) Plus FLT3-inhibitor (Midostaurin) Induction Therapy followed by Busulfan/Melphalan/Fludarabine Conditioning therapy and CD34+-selected allografts.",
"design_group_title": "Investigational Treatment",
"design_group_type": "Experime... | [
"Acute Myeloid Leukemia"
] | [
"Baptist Health South Florida, Inc."
] | [
"Jazz Pharmaceuticals Plc"
] | [
[
{
"name": "磷酸氟达拉滨",
"lang": "CN"
},
{
"name": "Fludarabine Phosphate",
"lang": "EN"
},
{
"name": "フルダラビンリン酸エステル",
"lang": "JP"
}
],
[
{
"name": "白消安",
"lang": "CN"
},
{
"name": "Busulfan",
"lang": "EN"
},
{... | null |
NCT03721510 | [
{
"id_field": "org_study_id",
"id_value": [
"IAVI T003"
]
}
] | https://clinicaltrials.gov/study/NCT03721510 | A Phase 1/2a Study of PGT121, VRC07-523LS and PGDM1400 Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults | This is a Phase 1/2a open label study to evaluate the safety, tolerability, pharmacokinetics and anti-viral activity of PGT121, VRC07-523LS and PGDM1400 for HIV prevention and therapy. | A Phase 1/2a Open Label Study of the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of PGT121, VRC07-523LS and PGDM1400 Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults | [
{
"description": "PGT121 + VRC07-523LS, dose 30 mg/kg each, given intravenously",
"name": "PGT121 + VRC07-523LS",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "PGT121 + VRC07-523LS + PGDM1400, dose 20 mg/kg each, given intravenously",
"n... | [
{
"design_group_description": "HIV-uninfected volunteers receiving one IV infusion",
"design_group_title": "Group 1A",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "P... | [
"HIV/AIDS"
] | [
"International AIDS Vaccine Initiative, Inc."
] | [
"Orlando Immunology Center P A",
"Beth Israel Deaconess Medical Center, Inc.",
"National Institute of Allergy & Infectious Diseases"
] | [
[
{
"name": "PGT-121",
"lang": "EN"
}
],
[
{
"name": "VRC-07-523",
"lang": "EN"
}
]
] | null |
NCT06307548 | [
{
"id_field": "org_study_id",
"id_value": [
"I-3670923"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2024-01256"
]
},
{
"id_domain": "Roswell Park Cancer Institu... | https://clinicaltrials.gov/study/NCT06307548 | Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer | This phase I/II trial studies the side effects and how well fluorescence image guided surgery followed by intraoperative photodynamic therapy for improving local tumor control in patients with colorectal cancer that has spread to nearby tissue or lymph nodes (locally advanced) or that has come back after a period of im... | Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Loco-Regionally Advanced or Recurrent Colorectal Cancer Undergoing Surgery - Phase I/II | [
{
"description": "Given PO",
"name": "Aminolevulinic Acid",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"5-ALA",
"5-Aminolaevulinic Acid",
"5-Aminolevulinic Acid",
"Amino-Levulinic Acid",
"Delta Aminolevulinic Acid",
"Delta-Aminolevulini... | [
{
"design_group_description": "Patients receive aminolevulinic acid PO 2 to 4 hours prior to SOC surgery. Patients then undergo image-guided fluorescence 5-10 minutes post surgery, and intraoperative PDT 15-45 minutes post surgery. Patients also undergo CT or MRI during screening and on follow up. Patients also... | [
"Locally Advanced Colorectal Carcinoma",
"Recurrent Colorectal Carcinoma",
"Stage III Colorectal Cancer"
] | [
"Roswell Park Comprehensive Cancer Center"
] | [
"National Center for Advancing Translational Sciences"
] | [
[
{
"name": "盐酸氨酮戊酸",
"lang": "CN"
},
{
"name": "Aminolevulinic Acid Hydrochloride",
"lang": "EN"
},
{
"name": "アミノレブリン酸塩酸塩",
"lang": "JP"
}
]
] | null |
NCT01868490 | [
{
"id_field": "org_study_id",
"id_value": [
"215-3-2552"
]
},
{
"id_field": "nct_alias",
"id_value": [
"NCT01573455"
]
}
] | https://clinicaltrials.gov/study/NCT01868490 | The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK Cells | Cytokine-induced killer (CIK) cells exhibit high proliferation rate and cytotoxic activity in vitro. The major effector cells are the CD3+CD56+ subset. The cytolytic activity of CIK cells being independent of MHC restriction implies feasibility in using CIK cells allogeneic to the tumors. Experiments to block the MHC c... | Phase 1 Study of The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous Cytokine-induced Killer Cells. | [
{
"description": "at least 10*9 CIK cells, IV on day 0, 14, 28",
"name": "cytokine induced killer cells",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "single-group studies",
"design_group_title": "drug",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "at least 10*9 CIK cells, IV on day 0, 14,... | [
"Cholangiocarcinoma",
"Neuroblastoma"
] | [
"Siriraj Hospital"
] | [
"Mahidol University"
] | [
[
{
"name": "Autologous CIK Cells(Siriraj Hospital)",
"lang": "EN"
}
]
] | null |
NCT04194086 | [
{
"id_field": "org_study_id",
"id_value": [
"2018-EKZX-003"
]
}
] | https://clinicaltrials.gov/study/NCT04194086 | Population Pharmacokinetics and Safety of Oral Posaconazole in Children With Leukemia | This study is designed to evaluate the safety, efficacy and Population Pharmacokinetics of Oral Posaconazole in Children with leukemia. | Population Pharmacokinetics and Safety of Oral Posaconazole in Children With Leukemia | [
{
"description": "posaconazole oral suspensions（5mg/kg/d,tid) will be administered specially febrile neutropenia patients four times a day and blood samples will be taken any hours after the first dose at least Day 7.",
"name": "posaconazole oral suspensions",
"normalized_type": "3d1aa88261d64c038413723... | [
{
"design_group_title": "posaconazole as antifungal prophylaxis",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "posaconazole oral suspensions（5mg/kg/d,tid) will be administere... | [
"Leukemia, Acute"
] | [
"Zhujiang Hospital of Southern Medical University"
] | [
"Guangdong General Hospital"
] | [
[
{
"name": "泊沙康唑",
"lang": "CN"
},
{
"name": "Posaconazole",
"lang": "EN"
},
{
"name": "ポサコナゾール",
"lang": "JP"
}
]
] | null |
NCT00699842 | [
{
"id_field": "org_study_id",
"id_value": [
"07C.446"
]
},
{
"id_domain": "Celgene",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"RV-MDS-PI-244"
]
},
{
"id_domain": "CCRRC",
"id_field": "secondary_id",
"id_type": "Other Ide... | https://clinicaltrials.gov/study/NCT00699842 | A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients | Revlimid® (Lenalidomide) is indicated for a type of blood cancer, myelodysplastic syndrome (MDS), at 10mg for a specific type of myelodysplastic syndrome with a genetic abnormality called "deletion 5q" in Low and Intermediate-1 (INT-1) patients (staging system according to International Prognostic Scoring System (IPSS)... | A Phase I/II Optimal Dose Study of Lenalidomide in the Non-5q- LOW and INT-1 Risk MDS Patients | [
{
"description": "Dose Level Lenalidomide Schedule<br/>1. 15mg/day for d1-21 out of 28 days<br/>2. 20mg/day for d1-21 out of 28 days<br/>3. 25mg/day for d1-21 out of 28 days",
"name": "Lenalidomide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Revlimid"
],
"... | [
{
"design_group_description": "Lenalidomide will be given orally on day 1-21, followed by a 7day rest (28 day cycle). Cycles will be repeated every 28 days.",
"design_group_title": "Lenalidomide",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5... | [
"Myelodysplastic Syndrome",
"MDS",
"Low to Intermediate-1 MDS",
"Non-deletion 5q"
] | [
"Sidney Kimmel Cancer Center at Thomas Jefferson University"
] | [
"Celgene Corp."
] | [
[
{
"name": "来那度胺",
"lang": "CN"
},
{
"name": "Lenalidomide",
"lang": "EN"
},
{
"name": "レナリドミド水和物",
"lang": "JP"
}
]
] | null |
NCT06432166 | [
{
"id_field": "org_study_id",
"id_value": [
"MTI2024-CS01"
]
},
{
"id_domain": "Alzheimer's Drug Discovery Foundation",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number",
"id_value": [
"RC-201910-2019696"
]
},
{
"id_domain": "VUMC IRB",
"... | https://clinicaltrials.gov/study/NCT06432166 | 2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients | Investigators propose a phase 1b/2a, randomized, double-blind, placebo-controlled, parallel group dose finding and biomarker study to evaluate the safety, tolerability, and biomarker activity of 2-HOBA in 48 MCI/AD participants. Participants will be randomized 1:1:1:1 to receive 250, 500, 750 mg 2-HOBA acetate TID or p... | 2-Hydroxybenzylamine (2-HOBA) Phase 1b/2a Proof-of Concept, Dose-Finding, Biomarker Study in Early Alzheimer's Patients | [
{
"description": "2-hydroxybenzylamine acetate (2-HOBA) is taken three times per day for 16 weeks",
"name": "2-hydroxybenzylamine acetate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"2-HOBA"
],
"type": "Drug"
},
{
"description": "Placebo taken three... | [
{
"design_group_description": "Placebo treatment TID for 16 weeks.",
"design_group_title": "Placebo",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
"intervention_description": "Placebo taken thr... | [
"Alzheimer Disease",
"Mild Cognitive Impairment"
] | [
"MTI Biotech, Inc."
] | [
"Vanderbilt University Medical Center"
] | [
[
{
"name": "2-羟基苄胺",
"lang": "CN"
},
{
"name": "2-Hydroxybenzylamine",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "2-HOBA"
}
] |
NCT00006968 | [
{
"id_field": "org_study_id",
"id_value": [
"CDR0000068349"
]
},
{
"id_field": "secondary_id",
"id_value": [
"UCLA-0001032"
]
},
{
"id_field": "secondary_id",
"id_value": [
"SUPERGEN-UCLA-000103201"
]
},
{
"id_field": "secondary_id",
"id_valu... | https://clinicaltrials.gov/study/NCT00006968 | Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with donor peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.<br/>PURPOSE: Phase I/II trial to study... | Non-Myeloablative Chemotherapy Followed By Related Allogeneic Stem Cell Rescue In Patients With Advanced Renal Cell Carcinoma | [
{
"name": "filgrastim",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"single_or_multi": "single_drug",
"type": "Biological"
},
{
"name": "cyclosporine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
... | null | [
"Kidney Cancer"
] | [
"Jonsson Comprehensive Cancer Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "环孢素",
"lang": "CN"
},
{
"name": "Cyclosporine",
"lang": "EN"
},
{
"name": "シクロスポリン",
"lang": "JP"
}
],
[
{
"name": "非格司亭 （安进）",
"lang": "CN"
},
{
"name": "Filgrastim (Amgen)",
"lang": "EN"
},
{
... | null |
NCT00964548 | [
{
"id_field": "org_study_id",
"id_value": [
"H-13076"
]
}
] | https://clinicaltrials.gov/study/NCT00964548 | Safety Study of Dantrolene to Treat Cerebral Vasospasm After Subarachnoid Hemorrhage | Subarachnoid hemorrhage (SAH) is a devastating acute brain injury due to bleeding onto the brain surface from a ruptured aneurysm. Cerebral vasospasm (cVSP; critical narrowing of brain arteries) is a known complication after SAH and significantly increases disability and death after SAH. Vasospasm is difficult to treat... | Dantrolene in the Treatment of Cerebral Vasospasm After Subarachnoid Hemorrhage - a Phase 1 Study | [
{
"description": "1.25 mg/kg IV once over 60 min",
"name": "Dantrolene",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "2.5 mg/kg IV once over 60 min",
"name": "Dantrolene",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type":... | [
{
"design_group_title": "Dantrolene (low dose)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "1.25 mg/kg IV once over 60 min",
"intervention_name": "Dantrolene",
... | [
"Cerebral Vasospasm After Subarachnoid Hemorrhage"
] | [
"University of Massachusetts"
] | [
"The General Hospital Corp."
] | [
[
{
"name": "丹曲林钠",
"lang": "CN"
},
{
"name": "Dantrolene Sodium",
"lang": "EN"
},
{
"name": "ダントロレンナトリウム水和物",
"lang": "JP"
}
]
] | null |
NCT04923542 | [
{
"id_field": "org_study_id",
"id_value": [
"MCC-20899"
]
},
{
"id_field": "secondary_id",
"id_value": [
"MCC-20899"
]
}
] | https://clinicaltrials.gov/study/NCT04923542 | Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases | This is a single arm study of abemaciclib and endocrine therapy with stereotactic radiosurgery (SRS) among patients with hormone receptor (HR)+/HER2- metastatic breast cancer brain metastases. | Phase I/II Study of Stereotactic Radiation and Abemaciclib in the Management of Hormone Receptor Positive HER2 Negative Breast Cancer Brain Metastases | [
{
"description": "Patients will receive single session SRS to intact brain metastases and post-operative cavities. For intact brain metastases, this will be 15 Gy to lesions between 31-40 mm, 18 Gy to 21- 30 mm, and 24 Gy to lesions measuring ≤ 20 mm.",
"name": "Stereotactic Radiosurgery (SRS)",
"normal... | [
{
"design_group_description": "Treatment will be initiated with one week of abemaciclib followed by stereotactic radiation to sites of brain metastases or post-operative cavities with continued abemaciclib. In the phase I portion, safety will be monitored initially by a 3+3 design. If unexpected neurologic toxi... | [
"Brain Metastases",
"HR+ Metastatic Breast Cancer"
] | [
"H. Lee Moffitt Cancer Center & Research Institute, Inc."
] | [
"Eli Lilly & Co."
] | [
[
{
"name": "阿贝西利",
"lang": "CN"
},
{
"name": "Abemaciclib",
"lang": "EN"
},
{
"name": "アベマシクリブ",
"lang": "JP"
}
]
] | null |
NCT01165112 | [
{
"id_field": "org_study_id",
"id_value": [
"PSOC 2502"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2010-00907"
]
},
{
"id_domain": "Fred Hutchinson Cancer Rese... | https://clinicaltrials.gov/study/NCT01165112 | Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma | This phase I/II trial is studying the side effects and best dose of bendamustine hydrochloride when given together with carboplatin, etoposide, and rituximab in treating patients with diffuse large B cell lymphoma or Hodgkin lymphoma that has come back after a period of improvement or has not responded to previous trea... | A Phase I/II Trial of Bendamustine/Treanda®, Rituximab, Etoposide, and Carboplatin for Patients With Relapsed or Refractory Lymphoid Malignancies and Select Untreated Lymphomas (TREC) | [
{
"description": "Given IV",
"name": "Bendamustine Hydrochloride",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Ribomustin",
"SyB L-0501",
"Treanda"
],
"type": "Drug"
},
{
"description": "Given IV",
"name": "Carboplatin",
"normaliz... | [
{
"design_group_description": "Patients receive bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, etoposide IV over 60 minutes on days 1-3, and carboplatin IV over 60 minutes on day 1. Patients with CD20+ T-cell lymphoma disease also receive rituximab IV on day 2 or 3. Treatment repeats every 21... | [
"Recurrent Adult Diffuse Large Cell Lymphoma",
"Recurrent Adult Hodgkin Lymphoma"
] | [
"University of Washington"
] | [
"National Cancer Institute"
] | [
[
{
"name": "盐酸苯达莫司汀",
"lang": "CN"
},
{
"name": "Bendamustine Hydrochloride",
"lang": "EN"
},
{
"name": "ベンダムスチン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "依托泊苷",
"lang": "CN"
},
{
"name": "Etoposide",
"lang": "EN"
},
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "50249a59a9a2a990aa04a2288e4922ea",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "TREC"
}
] |
NCT04077866 | [
{
"id_field": "org_study_id",
"id_value": [
"SAHZJU-RCT-BP102"
]
}
] | https://clinicaltrials.gov/study/NCT04077866 | B7-H3 CAR-T for Recurrent or Refractory Glioblastoma | This is a randomized, parallel-arm, phase I/II study to evaluate the safety and efficacy of B7-H3 CAR-T in between Temozolomide cycles comparing to Temozolomide alone in treating patients with glioblastoma that has come back or does not respond to the standard treatment. The antigen B7-H3 is highly expressed in gliobla... | B7-H3-Targeted Chimeric Antigen Receptor (CAR) T Cells in Treating Patients With Recurrent or Refractory Glioblastoma | [
{
"description": "Temozolomide is an FDA-approved drug that is given to patients",
"name": "Temozolomide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"TMZ"
],
"type": "Drug"
},
{
"description": "B7-H3-targeting CAR-T cells derived from patient own pe... | [
{
"design_group_description": "Temozolomide will be given to patients orally every 5 days with 23 days interval. The initial dose is 150 mg/m2 on the first day and 200 mg/m2 for the rest if no toxicity is seen. If 200 mg/m2 is toxic, the drug will return to 150 mg/m2 or will be stopped.",
"design_group_titl... | [
"Recurrent Glioblastoma",
"Refractory Glioblastoma"
] | [
"The Second Affiliated Hospital Zhejiang University"
] | [
"Boyuan Runsheng Pharmaceutical (Hangzhou) Co., Ltd.",
"Yinzhou People's Hospital",
"Huizhou Central People's Hospital"
] | [
[
{
"name": "Anti B7 H3 CAR-T-cell therapy (BoYuan RunSheng Pharma)",
"lang": "EN"
}
],
[
{
"name": "替莫唑胺",
"lang": "CN"
},
{
"name": "Temozolomide",
"lang": "EN"
},
{
"name": "テモゾロミド",
"lang": "JP"
}
]
] | null |
NCT04488107 | [
{
"id_field": "org_study_id",
"id_value": [
"AH150201"
]
}
] | https://clinicaltrials.gov/study/NCT04488107 | Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c | This is a multicenter, open, single arm dose escalation and dose expansion clinical study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of FCN-437c alone or in combination with letrozole in women with ER +/ HER2 - advanced breast cancer. | A Multicenter, Open, Single Arm Dose-escalation and Dose-expansion Study: to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of FCN-437c Alone or in Combination With Letrozole in ER+/ HER2- Advanced Breast Cancer | [
{
"description": "- FCN-437c is a selective and potent CDK4/6 dual inhibitor, with broad antitumor activity in preclinical pharmacology models, favorable physical and pharmacokinetic (PK) properties, and acceptable toxicity profile in nonclinical studies.",
"name": "FCN-437c",
"normalized_type": "3d1aa8... | [
{
"design_group_description": "* This study plans to start escalating from 50 mg QD, through 100 mg, 200 mg, 300 mg, 450 mg, to 600 mg.<br/>* Participants will receive FCN-437c in sequential 28-day cycles which are made up of monotherapy QD for 21 days followed by a 7 day rest period.<br/>* Participants must be... | [
"Breast Neoplasms"
] | [
"Jinzhou Ahon Pharmaceutical Co., Ltd."
] | [
"Sir Run Run Shaw Hospital",
"Zhejiang Cancer Hospital",
"Fudan University"
] | [
[
{
"name": "来曲唑",
"lang": "CN"
},
{
"name": "Letrozole",
"lang": "EN"
},
{
"name": "レトロゾール",
"lang": "JP"
}
],
[
{
"name": "枸橼酸伏维西利",
"lang": "CN"
},
{
"name": "Fovinaciclib",
"lang": "EN"
}
]
] | null |
NCT03330795 | [
{
"id_field": "org_study_id",
"id_value": [
"DAIT BOLT-BMT"
]
},
{
"id_domain": "NIAID, NIH",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"DAIT RTB-003"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
... | https://clinicaltrials.gov/study/NCT03330795 | Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant | The purpose of this study is to determine whether bilateral orthotopic lung transplantation (BOLT) followed by cadaveric partially-matched CD3+/CD19+ depleted bone marrow transplant (BMT) is safe and effective for individuals aged 10 through 45 years with the diagnosis of primary immunodeficiency (PID) and end-stage lu... | Bilateral Orthotopic Lung Transplant in Tandem With CD3+ and CD19+ Cell Depleted Bone Marrow Transplant From Partially HLA Matched Cadaveric Donors (RTB-003) | [
{
"description": "Negative selection for CD3/CD19 will be performed on a CliniMACS? depletion device within 36 hours of collection, and cryopreserved for later marrow transplantation. BMT conditioning and transplantation will start at least 8 weeks or more post lung transplant - once the participant is clinical... | [
{
"design_group_description": "Participants may receive a double lung transplant followed by a bone marrow (hematopoietic stem cells) transplant, if a partially HLA-matched organ offer is accepted. The lungs and allogeneic hematopoietic stem cells will be from the same partially HLA-matched cadaveric donor. Pri... | [
"Primary Immunodeficiency",
"PID"
] | [
"National Institute of Allergy & Infectious Diseases"
] | [
"Pharmaceutical Product Development LLC",
"University of Pittsburgh"
] | [
[
{
"name": "CD3/CD19 neg allogeneic BMT(National Institute of Allergy & Infectious Diseases)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "a82e258eae82a459d9a2d92a52e925a4",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "BOLT-BMT"
}
] |
NCT07460986 | [
{
"id_field": "org_study_id",
"id_value": [
"MedOPP0799"
]
},
{
"id_field": "acronym",
"id_value": [
"BEXAR"
]
},
{
"id_field": "secondary_id",
"id_value": [
"MedOPP0799"
]
}
] | https://clinicaltrials.gov/study/NCT07460986 | A PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF BEXMARILIMAB IN COMBINATION WITH DOXORUBICIN IN METASTATIC SOFT-TISSUE SARCOMA | This trial will Study a type of sarcoma defined metastatic soft-tissue sarcoma (STS). Participants will be treated with bexmarilimab, a CLEVER-1 antibody plus doxorubicin, a chemotherapy. The main purpose of the Study is to analyze the safety (to find out how safe or toxic a treatment is to appropriately manage the ris... | A PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF BEXMARILIMAB IN COMBINATION WITH DOXORUBICIN IN METASTATIC SOFT-TISSUE SARCOMA | [
{
"description": "RP2D of bexmarilimab administered as IV infusion on D1 of 21-day cycle for 6 cycles.",
"name": "bexmarilimab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "75 mg/m2 doxorubicin administered as IV infusion on D1 of 21-day cycle f... | [
{
"design_group_description": "Participants will be randomized based on histological subtype, age (≥ 60 years old vs <60 years old) and ECOG status (0 vs 1) to receive RP2D of bexmarilimab plus doxorubicin (arm A) for 6 cycles. Then, participants will receive RP2D of bexmarilimab monotherapy (arm A) until unacc... | [
"Sarcoma of Soft Tissue"
] | [
"Medica Scientia Innovation Research SL"
] | [
"Faron Pharmaceuticals Oy"
] | [
[
{
"name": "盐酸多柔比星",
"lang": "CN"
},
{
"name": "Doxorubicin Hydrochloride",
"lang": "EN"
},
{
"name": "ドキソルビシン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "贝马瑞利单抗",
"lang": "CN"
},
{
"name": "Bexmarilimab",
"lang": "EN"
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "BEXAR"
}
] |
NCT01317992 | [
{
"id_field": "org_study_id",
"id_value": [
"U1111-1119-9613"
]
},
{
"id_domain": "The University of Adelaide",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"IBU-002"
]
}
] | https://clinicaltrials.gov/study/NCT01317992 | Ibudilast in the Treatment of Medication Overuse Headache | The purpose of this study is to determine if ibudilast is effective in reverting patients with medication overuse headache suffering chronic daily headache back to their original episodic headache pattern. | Ibudilast in the Treatment of Medication Overuse Headache: A Double-blind, Randomised, Placebo-controlled Pilot Study | [
{
"description": "Ibudilast 4 x 10 mg capsules, orally, twice daily for 8 weeks.",
"name": "Ibudilast",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Placebo 4 capsules, orally, twice daily for 8 weeks.",
"name": "Placebo",
"normalized_typ... | [
{
"design_group_description": "To receive ibudilast 40mg twice daily for 8 weeks.",
"design_group_title": "Ibudilast",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Ibudil... | [
"Medication Overuse Headache"
] | [
"University of Adelaide"
] | [
"University of South Australia"
] | [
[
{
"name": "异丁司特",
"lang": "CN"
},
{
"name": "Ibudilast",
"lang": "EN"
},
{
"name": "イブジラスト",
"lang": "JP"
}
]
] | null |
NCT04894240 | [
{
"id_field": "org_study_id",
"id_value": [
"MON-2021-001"
]
}
] | https://clinicaltrials.gov/study/NCT04894240 | A Study of Monepantel in Individuals With Motor Neurone Disease | Amyotrophic lateral sclerosis/ Motor Neurone Disease (ALS/MND) is a rare and invariably fatal neurological disease. ALS/MND has a terribly high burden on patients, family and carers, and carries great socioeconomic burden. Current best treatment options are expensive and attempt to control disease progression and manag... | A Phase I Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy Study of Oral Monepantel in Individuals With Motor Neurone Disease | [
{
"description": "Monepantel is provided to individuals living with ALS/MND as a white oval tablet to be administered once a day following meals",
"name": "Monepantel",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Monepantel tablets will be administered to participants in this arm daily for 28 days. Dose escalation will occur at the end of each 28 day period according to a modified Fibonacci sequence based upon recommendations from the safety management committee",
"design_group_title":... | [
"Motor Neuron Disease"
] | [
"Neurizon Therapeutics Ltd."
] | [
"Macquarie University",
"Little Co. of Mary Health Care Ltd.",
"Cure For Mnd Foundation, Inc."
] | [
[
{
"name": "Monepantel",
"lang": "EN"
}
]
] | null |
NCT05718037 | [
{
"id_field": "org_study_id",
"id_value": [
"BV-C211-202301"
]
}
] | https://clinicaltrials.gov/study/NCT05718037 | Phase I Clinical Trial of a Candidate Herpes Zoster Vaccine | This is a phase I, randomized, observer-blinded study to evaluate the safety, tolerability, and immunogenicity of BV211(a herpes zoster vaccine) in Adult Volunteers. | A Phase I, Randomized, Observer-blinded Study to Evaluate the Safety, Tolerability, and Immunogenicity of BV211 in Adult Volunteers | [
{
"description": "0.5mL, Intramuscular",
"name": "Recombinant Zoster Vaccine",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"BV211"
],
"type": "Biological"
},
{
"description": "0.5mL, Intramuscular",
"name": "Placebo",
"normalized_type": "30fae... | [
{
"design_group_description": "Young adult subjects received low dose of BV211",
"design_group_title": "LY",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "0.5mL, Intramusc... | [
"Herpes Zoster"
] | [
"Bravovax Co., Ltd."
] | [
"Shanghai Bovo Biotechnology Co., Ltd."
] | [
[
{
"name": "Recombinant Zoster Vaccine(BravoVax)",
"lang": "EN"
}
]
] | null |
NCT05160415 | [
{
"id_field": "org_study_id",
"id_value": [
"EDG-5506-002"
]
},
{
"id_field": "acronym",
"id_value": [
"ARCH"
]
}
] | https://clinicaltrials.gov/study/NCT05160415 | A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy | The ARCH study was an open-label, single-center, Phase 1b study of sevasemtem (EDG-5506) to assess the safety and pharmacokinetics (PK) of sevasemten in adults with Becker muscular dystrophy (BMD).<br/>Sevasemten is an investigational product intended to protect and improve function of dystrophic muscle fibers. | A Phase 1b, Open-label Study of the Safety and Pharmacokinetics of EDG-5506 in Adults With Becker Muscular Dystrophy | [
{
"description": "Daily oral dose of 10 mg daily until Visit 8 (Day 57), followed by 15 mg daily until Visit 13 (Month 6), followed by 20 mg until Visit 21 (Month 15), followed by 10 mg daily to Visit 27 (Month 24).",
"name": "Sevasemten",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"othe... | [
{
"design_group_description": "Drug: Sevasemten",
"design_group_title": "Treatment",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Daily oral dose of 10 mg daily until Vis... | [
"Becker Muscular Dystrophy"
] | [
"Edgewise Therapeutics, Inc."
] | [
"Medpace, Inc."
] | [
[
{
"name": "Sevasemten",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "2de290e85ea5052d9e2535a3825a28e8",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "322ae9083493484d8222a54e38ae82a5",
"s... |
NCT03258359 | [
{
"id_field": "org_study_id",
"id_value": [
"PACTN-02"
]
}
] | https://clinicaltrials.gov/study/NCT03258359 | Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN) | This study will evaluate the safety of autologous T cells that have been immunized ex vivo with patient-specific MDS stem cell neoantigens in patients with MDS. | A Phase 1 Clinical Trial of Personalized, Adoptive Cellular Immunotherapy Targeting Patient-specific Neoplastic Stem Cell Neoantigens (PACTN) in Patients With Myelodysplastic Syndromes (MDS) | [
{
"description": "To treat patients with MDS who have failed treatment with hypomethylating agents or have relapsed after treatment with hypomethylating agents or have declined hypomethylating therapy.",
"name": "PACTN",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}... | [
{
"design_group_description": "Open label 3+3 dose escalation phase 1 trial; 200 to 1000 mL of immunized T cells infused at 0.3, 1, and 3 x 10e7 nucleated cells/kg body weight.",
"design_group_title": "PACTN",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b35448... | [
"Myelodysplastic Syndromes"
] | [
"Persimmune, Inc."
] | [
"University of California San Diego"
] | [
[
{
"name": "Autologous T cell therapy (PersImmune)",
"lang": "EN"
}
]
] | null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.